key: cord-0921894-t36a6s2c
authors: Zhuang, Wei-Zhan; Lin, Yi-Heng; Su, Long-Jyun; Wu, Meng-Shiue; Jeng, Han-Yin; Chang, Huan-Cheng; Huang, Yen-Hua; Ling, Thai-Yen
title: Mesenchymal stem/stromal cell-based therapy: mechanism, systemic safety and biodistribution for precision clinical applications
date: 2021-04-14
journal: J Biomed Sci
DOI: 10.1186/s12929-021-00725-7
sha: 3951e4bf27b6564e4445d6aa11bb80a662472b3c
doc_id: 921894
cord_uid: t36a6s2c

Mesenchymal stem/stromal cells (MSCs) are a promising resource for cell-based therapy because of their high immunomodulation ability, tropism towards inflamed and injured tissues, and their easy access and isolation. Currently, there are more than 1200 registered MSC clinical trials globally. However, a lack of standardized methods to characterize cell safety, efficacy, and biodistribution dramatically hinders the progress of MSC utility in clinical practice. In this review, we summarize the current state of MSC-based cell therapy, focusing on the systemic safety and biodistribution of MSCs. MSC-associated risks of tumor initiation and promotion and the underlying mechanisms of these risks are discussed. In addition, MSC biodistribution methodology and the pharmacokinetics and pharmacodynamics of cell therapies are addressed. Better understanding of the systemic safety and biodistribution of MSCs will facilitate future clinical applications of precision medicine using stem cells. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12929-021-00725-7.

Cell therapy has become one of the most important emerging medical treatments in the world. Treatments utilizing stem cells, induced pluripotent stem cells (iPSCs), somatic cells, and immune cells are well documented [1] . Many cell therapy products have already received global market approval. Among them, the mesenchymal/stromal stem cells (MSCs) present a promising tool for the treatment of various diseases.

MSCs were first isolated and described by Friedenstein and his colleagues as adherent and highly replicative cells that can differentiate into mesodermal lineages including osteoblasts, chondrocytes, adipocytes, and hematopoietic stroma [2] . Since then, these cells have gained attention in the field of cell therapy for their tropism towards injured/inflamed tissues, their immunomodulatory capabilities [3] , and their relative ease of isolation and expansion [4] . MSCs can be isolated from many sources, including bone marrow [5] , umbilical cord [6] , adipose tissue [7] , cord blood [6] , placenta [8] , dental pulp [9] , endometrium [10] , amniotic fluid [11] , skeletal muscle tissue [12] , lung tissue [13] , liver tissue [7, 12] and dermal tissue [12] , and many of these cells have been used in clinical studies (Fig. 1a) . The characteristics of MSCs make them attractive as cellular therapeutic agents for regenerative medicine and immune-related diseases. Zhuang et al. J Biomed Sci (2021) 28:28 The first clinical trial of MSCs was reported in 1995 in patients with hematologic malignancies. Lazarus et al. demonstrated that ex vivo expansion and subsequent infusion of human bone marrow-derived stromal progenitor cells (BMMSCs) in patients caused no severe adverse effects [14] . Subsequently, treatment with BMMSCs was shown to provide clinical improvement in the rare skeletal disease osteogenesis imperfecta [15] . Furthermore, many clinical trials have examined the feasibility and efficacy of MSCs for the treatment of various conditions, including acute organ failure [16] [17] [18] , graft-versus-host disease (GVHD) [19] [20] [21] , ischemic heart disease [22, 23] , cardiovascular disease [24, 25] , liver cirrhosis [26] , diabetes [27, 28] , spinal cord injury [29] [30] [31] , and bone/cartilage injury [32] [33] [34] [35] [36] [37] (Table 1 ). According to the National Institutes of Health (http:// www. clini caltr ial. gov/), the number of registered MSC-based clinical trials was over 1,200 as of October 11, 2020, of which approximately 600 had defined phase and status (Fig. 1b , c, Additional file 1 and Additional file 2). Most of the studies to date are phase 1 and phase 2 trials which evaluate safety and feasibility, and evidence of therapeutic efficacy is still lacking (Fig. 1) . The most common indications of MSC-based cellular therapy include osteoarthritis, ischemic heart disease, graft-versus-host disease, spinal cord injury, and multiple sclerosis (Fig. 1c ). In addition, since the elevation of coronavirus disease-19 outbreak to pandemic status on March 11, 2020 [38] , numerous MSC-based studies have been registered, and COVID-19 related pneumonia and acute respiratory distress syndrome (ARDS) has risen as the second most common indication as of October 11, 2020 (Fig. 1c) . The rapid global response and increase of COVID-19 related MSC trials highlighted the promise of MSCs in treatment of inflammatory and immune diseases.

Although studies on MSCs are well-documented, MSCbased cellular products still have not been approved by the US Food and Drug Administration. The lack of consistent and standardized methods for characterizing the safety and efficacy of MSC products is a major concern, which dramatically slows the progress of MSC therapy towards clinical use. The safety of cellular products is always the first priority. Although some MSCs have been shown to be safe for clinical use in a previous meta-analysis, whether this conclusion can be extended to MSCs from other tissue origins or different culture conditions is still uncertain (Fig. 1a) [39] . The risk associated with MSC products centers around their capability to initiate and promote tumors. These risks, as well as the biodistribution of systemically administered cells must be better clarified before the widespread use of MSCs in clinical practice. In this review article, we focus on the effects of MSCs on tumor promotion and suppression, and discuss methods to study their biodistribution.

Several possible mechanisms by which MSCs exert their beneficial effects have been proposed. Early studies reported that MSCs could migrate to sites of injury and then differentiate into functional cells [40] , or that they could fuse with compromised cells to regenerate damaged tissues [41, 42] . More recent studies have demonstrated that paracrine factors [43, 44] , mitochondrial transfer [45] , and extracellular vesicle secretion [46] have important roles in mediating the effects of MSCs.

MSCs secrete paracrine factors, including cytokines, chemokines, growth factors, and miRNAs. MSC transplantation or administration of isolated secreted factors enables MSC paracrine factors to get to injured tissues, to help restore a healthy microenvironment to promote tissue repair [47] (Table 2) . MSC paracrine factors play important roles in immunomodulation [48, 49] , tissue regeneration and healing [50, 51] , anti-fibrosis [52, 53] , anti-apoptosis [54] , and angiogenesis [55] . As such, many studies have focused on altering culture conditions in order to steer the secretome of MSCs towards therapeutic agents. Alterations have included using MSCs from different types of tissue [56, 57] , oxygen concentration [58] , growth factor incubation or cytokine pretreatment [59] , passage number [60] [61] [62] , three-dimensional spheroid culturing [63] , and mechanical strain [64] .

The capability of MSCs for immunomodulation has made them a useful treatment approach for inflammatory disorders such as multiple sclerosis [65] , Crohn's disease [66] , GVHD [67] , systemic lupus erythematosus [67] , and type I diabetes [68] . Immunomodulation is dependent on crosstalk between MSCs and the immune microenvironment of the target tissue. In an inflammatory As of October 11, 2020, 1,242 registered studies were identified on clinicaltrials.gov by searching keywords "mesenchymal stem cell" or "mesenchymal stromal cell" (Additional file 1). After excluding studies with no longer available/ suspended/ temporarily not available/ terminated/ unknown/ withdrawn status, unknown phase information, and studies that did not use MSCs in their intervention arm, 639 studies remained. Nine of these 639 studies investigated MSCs from two tissue origins, generating a total of 648 studies for analysis. 28:28 microenvironment, proinflammatory cytokines, including IL-1β, IL-6, IL-23, IFN-γ, and TNF-α, can stimulate MSCs to secrete anti-inflammatory factors such as TNFα stimulated gene (TSG)-6 [69] , nitric oxide (NO) [70] , IL-10 [71] , galectins [72] , prostaglandin E2 (PGE2) [73] , and transforming growth factor (TGF)-β [3, 71] . Upon exposure to these MSC-secreted anti-inflammatory signals, nuclear factor (NF)-κB activity and consequent inflammatory cytokine expression in macrophages, dendritic cells, and T cells are inhibited, and immune cells will express higher levels of anti-inflammatory cytokine IL-10 as a result [3, 74] . The MSC paracrine factors also interact with other immune cells and have been reported to skew macrophage polarization towards the M2 phenotype, which downregulates both innate and adaptive immune responses [75] . Regulatory T cells (Treg) were also reported to stimulate MSCs to secrete indoleamine 2,3-dioxygenase (IDO), thereby augmenting the Treg response and attenuating acute liver injury [3, 76] .

In addition to their immunomodulation ability, MSCs are able to secrete factors that can promote cell proliferation, increase angiogenesis, and reduce cell apoptosis. For example, MSCs can secrete growth and angiogenesis-promoting factors such as basic fibroblast growth factor (bFGF) [77] , insulin-like growth factor (IGF) [78] , TGF-β [3, 55] , stromal cell-derived factor (SDF)-1α [79] , secreted frizzled-related protein-1/2 (SFRP1/2) [80, 81] , angiopoietins, and vascular endothelial growth factor (VEGF) [82, 83] .

It has been demonstrated that MSCs can inhibit fibrosis via paracrine factors [84] . Chronic inflammation is a major factor that drives the fibrosis process, which can alter the normal architectural structure of tissues and lead to deteriorated functioning. Because MSCs can be used to reduce inflammation, they have become an attractive therapeutic strategy for suppressing fibrosis. MSC-derived conditioned medium (CM) was shown to attenuate liver fibrosis by reducing Th17 cells in a [125, 132, 133, 139, 147, 150, 159, 162, 165] Chemokines SDF-1, CXCL1, CCL2, CCL5 [123, 124, 136, 142-144, 150, 160, 162] Angiogenic factors VEGF, Ang-1, PDGF, IGF [148, 162] Growth factor NRG1 [135] Other factors periostin, PAI-1, Sema-7A [134, 162] microRNAs miR-21-5p, miR-410, MiR-142-3p, miR-23b [126, 136, 145, 158] IDO-dependent manner [85] . MSC-secreted interleukin 1 receptor antagonist (IL-1Ra) was also shown to inhibit stellate cell activation and decrease type I collagen expression, a key component of liver fibrosis [86] . Administration of MSC-CM also reduced fibrotic score and collagen deposition in both bleomycin-and silicainduced lung injury models [87, 88] . In MSC-treated cells, levels of HGF, KGF, and BMP-7 increased while levels of TGF-β1 and TNF-α decreased. These results suggest that the anti-fibrotic effect of MSCs may be mediated via paracrine mechanisms [88] . In support of this, a bleomycin-induced lung injury model showed that the stanniocalcin-1 (STC-1) secreted by MSCs in response to TGF-β1 exerted antifibrotic effects by reducing oxidative stress, endoplasmic reticulum (ER) stress, and TGF-β1 production in alveolar epithelial cells [89] . Likewise, MSCs were able to decrease the expression of fibrosis-associated tissue inhibitor of matrix metalloproteinase 1 (TIMP)-1, to improve cardiac function in a myocardial infarction model [90] .

Mitochondrial dysfunction is a hallmark of the aging process, and has been implicated in the pathogenesis of numerous diseases [91] . MSC-based mitochondrial transfer has therefore been a promising therapeutic strategy, by either replenishing or replacing the damaged mitochondria in targeted diseased cells [92] . Studies have observed increased tunneling nanotube (TNT) and gap junction formation with mitochondrial transfer between MSCs and injured epithelial/endothelial cells under inflammatory or hypoxic conditions, and MSCderived mitochondria transfers could prevent apoptosis of recipient cells [93] [94] [95] . In addition, it was found that iPSC-derived MSCs could attenuate alveolar damage and fibrosis via mitochondrial transfer by TNT [96] . The tissue origin of MSCs may affect mitochondrial transfer ability. For example, iPSC-derived MSCs were shown to be more effective at mitochondria transfer compared with MSCs derived from bone marrow [96] . Mechanistically, mitochondrial transfer was found to alleviate epithelial injury through mitochondrial Rho-GTPase Miro1 regulation in an asthma model [97] . Despite these beneficial findings of MSC-mediated mitochondrial transfer, there are also potential risks, as mitochondrial transfer can increase the risk of tumor promotion. In acute myeloid leukemia (AML), NOX2 stimulated mitochondrial transfer from BMMSCs to cancer cells, and this promoted the survival of the cancer cells [98] . Mitochondrial transfer also increased the resistance of leukemic cells to chemotherapeutic agents, and transfer occurred bidirectionally [99, 100] . In an in vitro co-culture of BMMSCs and T cell acute lymphoblastic leukemia (T-ALL) cells, upon induction of oxidative stress by the addition of chemotherapeutic agents, T-ALL cells transferred their mitochondria to BMMSCs, but received few mitochondria from the BMMSCs, raising the chemoresistance of the T-ALL cells [99] . Neutralizing the cell adhesion molecule ICAM-1 and disrupting intercellular mitochondrial transfer restored the sensitivity of the T-ALL cells to the chemotherapeutic agent [99] .

MSC-derived extracellular vesicles (EVs) have raised increasing interest as a non-cellular alternative to MSCbased therapy, as this approach eliminates concerns of unintended lineage differentiation [101] . EVs refer to exosomes, microvesicles, and apoptotic bodies, and are membrane-enclosed entities secreted by a cell in response to stimulation or apoptosis. The size and contents of these vesicles are highly variable and heterogeneous, involving proteins, mRNAs, and miRNAs [101] . Their role in MSC-mediated cellular therapy remains elusive due to their heterogeneous nature, but it is currently believed that they play an important role in many biological processes and intercellular communication [101] .

Exosomes from MSCs have shown beneficial effects in disease models of autoimmune uveitis [102] , retinal detachment [103] , myocardial infarction [104] , type 1 diabetes [105] , wound healing [106] , bone repair [107] , burn injury [46] , traumatic brain injury [108] , spinal cord injury [109] , and several other conditions [110] . The most commonly suggested mechanism responsible for the effects of exosomes is via their capability to regulate immune cells and immune microenvironments. MSCderived exosomes can suppress the expression of proinflammatory cytokines TNF-α, IL-1β, IL-6, IL-17, IFN-γ, and MIP-1α in immune cells [103, 105, 109, 111] . Additionally, MSC-derived exosomes significantly increased the levels of anti-inflammatory cytokines IL-4, IL-10, and TGF-β in a type 1 diabetes animal model [105] . In a drug-induced liver injury model, MSC-derived exosomes enhanced the local expression of cytokines TGF-β and HGF, both of which are key factors in liver regeneration [112] . The underlying mechanism involved changes in the immune cell population, including increased M2 polarization [106, 108, 109] , increased Th2 and regulatory T cell differentiation [105, 112] , decreased Th17 differentiation [111] , and decreased local immune cell infiltration [102] .

In addition to promoting immunomodulation, MSC-derived exosomes participate in other biological processes. MSC-derived exosomes were found to promote neoangiogenesis in diabetic and burn wounds via increased VEGF-A expression, the Wnt4/β-catenin pathway, and increased tube formation and proliferation of endothelial cells [106, 113] . MSC-derived exosomes also activate Akt, ERK, and STAT3 pathways and induce expression of HGF, IGF1, NGF, SDF1, and TGF-β, which critically regulate wound healing and tissue repair [114] . In addition, MSC-derived exosomes can aid in tissue repair by enhancing autophagy and inhibiting apoptosis [103] .

In contrast to microvesicles and exosomes from MSCs, apoptotic bodies are entities specifically generated by cells during apoptosis. Apoptotic bodies containing ubiquitin ligase RNF146 and miR328-3p were shown to help maintain MSC multipotency via the Wnt/β-catenin pathway [115] . In support, it was recently shown that apoptotic bodies released from donor MSCs improved myocardial infarction via autophagy regulation in recipient cells [116] .

The lack of consistent or standardized methods to isolate and identify EVs presents a challenge for current therapeutics. A recent study has shown that compared to EVs, MSC-CM resulted in more effective immunomodulation [117] . Further studies are necessary to decipher the optimal MSC culture conditions and the specific subpopulations of secreted components that contribute to the most effective therapeutic benefit.

Clinical applications of MSC-derived EVs have gained increasing interest, as many of the safety concerns of MSC-based therapy might be avoided, including undesired differentiation of implanted cells in tumor formation/promotion risks, and the cell-derived secondary ischemic damage by vessel clotting. As MSC-derived EVs are still in their clinical infancy, there is currently little information on clinical safety. To monitor biodistribution, most of the in vivo studies utilize lipophilic dyes to label the EVs [118, 119] . While the injected MSC-derived EVs migrated and accumulated at the injured tissue, they also aggregated in the lung, liver, and spleen [118, 119] .

MSC-related cell therapy is a promising therapeutic strategy because of the high immune modulation ability and the absence of tumor initiation risk of MSCs. However, there is still concern that MSCs can pose a risk for promoting tumor cell growth [120, 121] . MSCs share some characteristics with fibroblast cells, which are able to transform into cancer-associated fibroblasts (CAFs) in tumor niches. The tumor niche involves local fibroblasts, endothelial cells, immune cells, and cancer associated MSCs. Increasing evidence shows that the tumor niche is not only trophic to cancer cells, but also highly associated with tumor initiation and growth, and is able to increase cancer stemness-related properties, including the capacity for cell migration, invasion, and chemotherapy resistance. Therefore, cancer treatment strategies have expanded from solely targeting the tumor cells, to altering the tumor milieu.

Since MSCs have an excellent ability for homing to tumor sites, the possibility for therapeutic MSCs to transform into cancer-associated MSCs exists. Several studies have examined the effect of MSCs on different types of tumor cells. Not surprisingly, conclusions among these studies are unclear (Fig. 2 ). Studies using MSCs from different tissue origins, different cultivation processes, and different cancers can lead to diverse results and interpretations.

On the other hand, taking advantage of the ability of MSCs to home to tumor sites enables MSCs to serve as therapeutic carriers that deliver anticancer agents to appropriate sites [122] . As highly progressive and late stage malignancies constitute a major health burden, for which current treatments are unsatisfactory and curative therapies are unavailable, MSC-related drug carriers may provide new hope for cancer treatments, particularly for late stage cancers.

The underlying mechanisms responsible for MSC tumor promotion are complicated and diverse (Table 3) . They are classified below according to MSC type and signaling pathway, and are listed systematically in Table 4 and summarized in Fig. 3 .

Several studies have examined the effects of MSCs on tumor cell growth (Fig. 2 ). MSCs derived from human bone marrow (hBMMSCs) have been shown to enhance the motility of prostate cancer cells via SDF-1 regulation in vitro [123] . Additionally, hBMMSCs were reported to promote glioblastoma bone metastasis in vivo through the activation of SDF-1/CXCR4 and SDF-1/CXCR7 signaling [124] . It has also been shown that exosomes derived from glioma cells induce hBMMSC transformation to a tumor-like phenotype by activating glycolysis [125] . hBMMSCs that were pre-challenged with hypoxia increased tumor growth, cell proliferation, intra-tumoral angiogenesis and M2 polarization of macrophages in lung adenocarcinomas. The underlying mechanism involved downregulation of PTEN, PDCD4 and RECK gene expression by miR-21-5p derived from hBMMSCs exosomes [126] . Furthermore, hBMMSCs were shown to mediate osteosarcoma and hepatocellular carcinoma (HCC) cell migration and invasion through the regulation of CXCR4 [127] . Human MSCs (hMSCs) promote HCC tumor growth via the MAPK pathway and promote metastasis by epithelial-mesenchymal transition (EMT) and integrin α5. Furthermore, hMSC treatment promoted HCC progression, increased IL-6 and TNF-α expression, and decreased the number of natural killer (NK) cells in tumor niches [128] .

In addition to their paracrine effect, hBMMSCs also promote colorectal carcinoma (CRC) and gastric cancer progression by directly differentiating to CAFs and exerting their trophic effects [129] [130] [131] . In colorectal adenocarcinomas, IL6 secreted from hBMMSCs not only increased cancer cell CD133 expression via activation of the JAK2/STAT3 pathway [132] , but also activated Akt and ERK in endothelial cells by inducing the secretion of endothelin-1 (ET-1) [133] . Furthermore, hBMMSC-secreted PAI-1 and NRG1 were shown to promote CRC progression; the latter activates the PI3K/AKT pathway in a HER2/HER3-dependent manner [134, 135] . Indirect co-culture of CRCs with hBMMSCs enhanced the invasiveness of CRCs via suppression of RNA-binding protein PTBP1 [136] . The up-regulation of cancer stemness-related properties in CRCs is correlated with activation of the Notch signalling pathway by miR-142-3p, which downregulates Numb expression and is transmitted via hBMMSC exosomes [136] .

One approach to mimic the inflammatory niche is to generate TNF-α-primed-hBMMSCs that secrete high levels of CCL5, which is involved in the CRC-related CCl5/CCR1/β-catenin/Slug signaling pathway that promotes tumor cell proliferation, EMT, migration, and invasion [137] . Activation of the Hedgehog signaling pathway by hBMMSC-derived exosomes leads to increased tumor cell growth in both gastric cancer and in osteosarcoma [138] . hBMMSC-secreted IL6 and IL-8 have been shown to increase tumor growth and metastasis in osteosarcomas by activation of the STAT3 and FAK signaling pathways, respectively [139, 140] . Meanwhile, elevated levels of GRO-a, MCP-1, IL-6 and IL-8 in the tumor microenvironment promoted osteosarcoma invasion and transendothelial migration via cross-talk between tumor cells and CAFs from hBMMSCs [141] . CCL5 secreted by hBMMSCs increased the motility of breast cancer cells (BCCs) by activation of CCL5-CCR5 signaling [142] . This signalling also promotes BCCs to secret CSF1, which will bind to the CSF1 receptor on MSCs, tumor-associated macrophages and myeloid-derived suppressor cells, and drive recruitment of myeloid-derived suppressor cells (MDSCs) and tumor-associated macrophage (TAMs) [143] . Elevated CCL5 (RANTES), CCL2 (MCP-1), and CXCL8 (IL-8) in TNFα/IL-1β primed triple-negative subtype of breast cancer cells (TNBCs): hBMMSCs cocultures increase BCC lung metastases [144] . Moreover, physical interactions between TNBCs and hBMMSCs primed with TNFα or IL-1β, activates Notch1, which leads to CXCL8 production and increased tumor cell migration and invasion [144] . Exosomes derived from hBMMSCs promote the acquisition of dormant phenotypes by suppressing MARCKS expression in a bone marrow-metastatic human breast cancer cell line through miR-23b [145] . In head and neck squamous cell carcinoma (HNSCC) and esophageal squamous cell carcinoma (ESCC), increased tumor cell invasion was correlated with induction of ALP and MMP9 activity by direct contact between tumor cells and hBMMSCs, and by activation of the Gremlin1-dependent TGF-β/BMP signaling pathway by hBMMSC-CM, respectively [146, 147] 

The effect of MSCs on promoting tumor cell growth may be mediated via angiogenic factors VEGF, Ang-1, PDGF, and IGF and SDF-1 [148] . In addition, adipose tissue-derived mesenchymal stem cells (ADMSCs)differentiated CAFs promote the EMT of lung cancers by activating the NOTCH pathway [149] . hADMSCsecreted CXCL1/8 enhances the growth and angiogenesis of BCCs by activating CXCL1/8-CXCR1/2 signaling [150] . hADMSCs and human amniotic fluid-derived stem cells (hAFMSCs) increase ciprofloxacin resistance in renal cell carcinomas (RCCs) and bladder cancer cells [151] . Additionally, elevating the expression of MMP2 and MMP9 in ovarian cancer cells causes increased tumor growth and metastasis in both direct and indirect co-cultures with hADMSCs [152] . LL-37, which is usually overexpressed in ovarian cancer, can recruit and stimulate MSCs to release trophic factors, which increase tumor growth and angiogenesis [153] . In addition to MSCs, the CM and the EVs derived from human ADMSCs showed the ability to increase tumor growth and migration and to decrease H 2 O 2 -induced tumor cell apoptosis [154] . Meanwhile, the hADMSC-CM and exosomes were shown to increase doxorubicin resistance and tumor cell migration either by increasing breast cancer resistance protein (BCRP) levels or by activating the Wnt signaling pathway in BCCs, respectively [155, 156] . 

Glioma cell-derived exosomes, upregulating the levels of Glut-1, HK-2, and PKM-2, activating glycolysis in MSCs [125] Human bone marrow of healthy donor

Increased tumor metastasis SDF-1/CXCR4 and SDF-1/CXCR7 signaling [124] Human adipose tissue from trochanteric fat of healthy donor

Human adipose tissue

Higher mRNA expression levels of angiogenic factors (VEGF, Ang-1, PDGF, and IGF) and SDF-1(CXCL12) in MSCs [148] Mouse adipose tissue

Increased tumor migratory capacity MSC-secreted conditioned medium increases vimentin, MMP2, and NRAS expression [282] Human adipose tissue from individuals receiving abdominoplasty Human adipose tissue of individuals receiving abdominoplasty or mammoplasty

Increased cancer cell migration; no significant effect on cancer cell proliferation, TMZ response, CSC traits MSCs-CM [282] Human umbilical cord Wharton's jelly (human umbilical cord perivascular cells) Human umbilical cord of healthy donor Human umbilical cord Wharton's jelly [165] Human bone marrow from patients with orthopedic surgery

MSC-dependent activation of the CXCR4, PI3K/Akt, Ras/Erk pathways [127] Human bone marrow from ATCC

Increased tumor growth and metastasis Activated pERK signaling pathway and overexpressed integrin α5 in HCC; decreased NK cell marker CD56 and increased IL-6 and TNF-α in tumor niche [128] Colorectal cancer Human bone marrow of healthy donor

MSC-differentiated CAFs expressed PDGFR to mediate tumor growth and metastasis [130] Human bone marrow of healthy donor

MSC-differentiated into CAFs; paracrine effects of MSCs; [129] Human bone marrow of healthy donor

MSC-secreted PAI-1 promoted cancer cell migration [134] Human bone marrow of healthy donor Human bone marrow from sternum of healthy donor

Increased tumor growth, invasion; decreased survival MSC-secreted NRG1 activated HER2/HER3dependent PI3K/AKT pathway [135] Human bone marrow from iliac crest of healthy donor

Increased tumor growth and angiogenesis MSC-secreted IL6 induced ET1/AKT or ERK pathway in endothelial cells to promote angiogenesis [133] Human bone marrow from the iliac crest of the patient following bone defect reconstruction [153] Human adipose tissue from omentum of normal donors

Elevated the expression of MMP2 and MMP9 [152] Endometrial cancer Human adipose tissue from omentum of patient with recurrent adenocarcinoma of endometrium and ovary

Increased tumor growth and cell proliferation Not explored [283] Breast cancer Human bone marrow of healthy donor Not stated

MSCs involve in driving recruitment of TAMs and MDSCs [143] Human bone marrow of healthy donor Not stated

Activation of EGFR signaling pathway [284] Human bone marrow of healthy donor

Not stated

Tumor and stroma physical interactions activated Notch1 by TNFα or IL-1β, which further lead to CXCL8 production [144] Human bone marrow from Lonza [150] Human adipose tissue from patients undergoing tumescent liposuction

Exosomes derived from MSCs activated Wnt signaling pathway [155] Human adipose tissue from ScienCell Research Laboratories (Carlsbad, CA)

MSC-secreted conditioned medium promoted BCRP protein expression in cancer cells [156] Human adipose tissue from liposuction Human bone marrow from patients with orthopedic surgery

MSCs-dependent activation of the CXCR4, PI3K/Akt, Ras/Erk pathways [127] Human bone marrow

Activation of Hedgehog signaling pathway by MSC-derived exosomes [138] Human bone marrow from TaKaRa Biotechnology Not stated

Paracrine effect of IL-8 through activation of FAK pathway [140] Human bone marrow of healthy donor

MSCs trans-differentiate into CAFs, increasing GRO-a, MCP-1, IL-6 and IL-8 levels in the tumor microenvironment [141] Human bone marrow

Not explored [288] Gastric cancer Human bone marrow

Activation of Hedgehog signaling pathway by MSC-derived exosomes [138] Human bone marrow from ATCC Not stated

MSCs recruitment and presence of CAF-like myofibroblastic phenotypes by tumorderived HDGF [131] Head and neck cancer Human bone marrow from patients during hip-replacement surgery 

Human bone marrow

Gremlin1 derived from MSC-CM is related to TGF-β/BMP signaling pathway [147] Bladder cancer Human adipose tissue from liposuction

Not explored [151] Human amniotic fluid from healthy pregnant women 

hUCMSCs promote proliferation and migration of BCCs by activating ERK signaling, including down-regulating E-cadherin expression, and up-regulating N-cadherin, ZEB1 and PCNA expression [157] .

The EVs derived from hUCMSCs also have the ability to increase tumor cell proliferation and to decrease tumor cell apoptosis in lung adenocarcinomas via transmission of miR-410, which reduces PTEN expression [158] . Additionally, exosomes derived from hUCMSCs increased tumor EMT, invasion, and migration through TGF-β1-mediated signaling pathways [159] . Furthermore, CD133 + glioblastoma stem cells exhibited the ability to recruit hUCBMSCs, which can further promote tumor growth in vivo, via exosomes containing MCP-1/ CCL2 and SDF-1/CXCL12 [160] .

An increase in the cancer stemness-related ALDH + and CD133 + cell populations was observed in lung [161] . WJMSC-CM also showed effects of increasing tumor growth and migration of glioblastoma cells by secreted cytokines (eg. CCL2, PDGF-C, Sema-7A, periostin, IL6) [162] . Besides the cytokines and chemokines secreted by MSCs, WJMSC microvesicles (MVs) transfer RNA to RCCs, which induces HGF synthesis and further activates AKT and ERK1/2 signaling [163] .

Chemokine signaling plays an important role in MSCdependent tumor promotion (Fig. 3) . CD133 + glioblastoma stem cells induce hUCMSC migration to tumor regions by secreting CCL2 and CXCL12. Once in the tumor region, MSCs then promote tumor proliferation and glial invasiveness [160] . In addition, SDF-1 secreted from hBMMSCs promotes neuroblastoma migration and invasion via CXCR4 and CXCR7 [124] . hBMMSCs also enhance osteosarcoma and HCC cell migration and invasion by activating the AKT and ERK pathways of tumor cells via CXCR4 [127] . These observations suggest that chemokine signaling may be involved in bone metastasis. Furthermore, Chaturvedi et al. demonstrated that there is a delicate crosstalk among BCCs, hBMMSCs and TAMs/ MDSCs involving chemokine signaling, and that there are two signaling loops among these cell types. In the second loop, CCL5 secreted from MSCs activates BCCs via CCR5, which promotes the BCCs to secret CSF1 and further recruits TAMs and MDSCs to the tumor region [143] . In addition, hBMMSCs weakly enhance the invasiveness and metastasis of metastatic human BCCs through CCL5-CCR5 signaling regulation [142] . CCL5 secreted from TNF-α-primed hBMMSCs also showed the ability to promote CRC progression and EMT via the CCL5/CCR1/β-catenin/Slug signaling pathway [137] . In addition to tumor and immune cells, chemokine signaling affects other cells in tumor niches. For example, CXCL1/8 derived from hADMSCs can enhance the migration and tube formation of human umbilical vein endothelial cells (HUVECs) in vitro by CXCR1 and CXCR2, which promote angiogenesis in a breast tumor xenograft mouse model [150] . CXCL8 derived from hBMMSCs was also shown to activate FAK signaling in osteosarcomas and to promote tumor metastasis [140] .

TGF-β is well known as an EMT promotor, but it can also induce cell cycle arrest and apoptosis [164] . In lung cancer cells, hUCMSCs have been shown to promote tumor cell EMT, invasion, and migration, but also to decrease tumor proliferation and promote tumor apoptosis by TGF-β1 from exosomes secreted by MSCs. The TGF-β1 activates Smad2/3, Akt/GSK-3β/β-catenin, NF-kB, ERK, JNK, and the p38 MAPK signaling pathway in cancer cells. Silencing TGF-β1 or inhibiting exosome secretion can eliminate the MSC-dependent effects on cancer cells described above [159] . hBMMSCs also increased tumor progression, but decreased pulmonary metastasis with decreased TGFβ1 levels in HCC [165] . Furthermore, Hong et al. demonstrated that hBMMSC-CM can enhance the proliferation, viability and invasiveness of esophageal cancer cells via Gremlin1, which activates the TGF-β/Smad2/3 signaling pathway by inhibiting the BMP4/Smad1/5/8 signaling pathway in cancer cells [147] .

Accumulating evidence shows that EV-derived miRNA contributes to tumor initiation, angiogenesis, drug resistance, metastasis and immune suppression in cancer [166] . EVs derived from hBMMSCs pre-challenged with hypoxia can promote tumor growth, cancer cell proliferation, invasion, intra-tumoral angiogenesis and M2 polarization of macrophages in non-small cell lung cancer cells. This occurs via miR-21-5p, which decreases PTEN, PDCD4 and RECK protein levels in cancer cells while enriching for CD163 + CD206 + , M2 macrophagerelated cell surface marker macrophages, and decreasing the CD40 + CD86 + , M1 macrophage-related cell surface marker macrophage population. Transfecting miR-21-5p inhibitor or re-overexpressing PTEN abrogated the tumor promoting and M2 polarization effects that the hypoxia pre-challenged EVs induced [126] . Dong et al. also reported that miR-410 derived from hUCMSCsecreting EVs repressed PTEN protein levels in lung adenocarcinoma cells, further increased tumor cell proliferation, and decreased tumor cell apoptosis [158] .

miRNA is also reported to be involved in the dynamics of the cancer stem cell population. Increased cancer stem cell-like traits, including sphere formation, Lgr5 + CD133 + population, colony formation, drug resistance, and tumourigenesis, were reported in CRCs upon treatment with hBMMSC-derived exosomes that transmitted miR-142-3p. Mechanistically, it was found that miR-142-3p inhibits the expression of the Numb gene, which results in increased mRNA and protein levels of Notch target genes Hes1, P21, and cyclin D3 mRNA [136] . On the other hand, Ono et al. demonstrated that miR-23b delivered via hBMMSC-derived exosomes caused bone marrow-metastatic human breast cancer cells to acquire dormant phenotypes, characterized by decreases in tumor cell proliferation, tumourigenic capacity, CD44 + population, invasion capacity, and sensitivity to docetaxel. The miR-23b may exert its effects by targeting MARCKS [145] .

While MSCs utilize diverse mechanisms for tumor promotion, they suppress tumor growth mainly by inducing apoptosis of tumor cells. MSCs have been shown to suppress the growth of breast [167] [168] [169] , brain [148, [170] [171] [172] [173] [174] , lung [170, 175] , liver [175, 176] , ovarian [167, 177, 178] , bone [167, 179] , esophageal [168] , bladder [180] , colorectal [170] and hematological malignancies [181] [182] [183] . The underlying mechanisms responsible for MSC tumor suppression are classified below as well in Table 5 , and are summarized in Fig. 4 .

The majority of MSC tumor suppressing mechanisms involve increasing tumor cell apoptosis and impeding cell cycle progression. Upregulation of caspase-3, caspase-9, p16, p21, p53, TRAIL, pro-apoptotic BAX, ATG5, ATG7, BECLIN1 and cellular H 2 O 2 levels [148, 167-170, 173, 180, 182] ; activation of Smac/DIABLO [173] ; and downregulation of survivin, XIAP, cyclin D1, Cdk4, Cdk6, cyclin A2, cyclin E1, AKT/pAKT, Bcl-2, β-catenin, c-Myc, pro-caspase-7, PCNA, Bcl-xL and MMPs have been demonstrated to be involved in the MSC-dependent tumor cell apoptosis seen with MSC-CM, MSC cell lysate (CL) and with direct cell-cell interaction [167, 168, 170-176, 178, 180] .

The immunomodulation ability of MSCs is also correlated with tumor suppression. Lin et al. demonstrated that 3 kDa MWCO-WJMSC-CM concentrate can induce immunogenic cell death in lymphoma cells, which showed decreased viability and increased apoptosis, as well as increased levels of the ER stress markers eLF2a and XBP-1. Increased levels of surface damage-associated molecular pattern markers ecto-CRT, ecto-Hsp70 and ecto-Hsp90, as well as extracellular ATP and high mobility group box 1 were also observed. When cocultured with WJMSC-CM-treated lymphoma cells, dendritic cells had enhanced CD80 and CD86 expression. Yet lymphoma cells treated with WJMSC-CM concentrate had decreased CD47 and PD-L1 expression [181] .

In addition to directly inhibiting tumor cell growth, coculturing with hBMMSCs or hUCBMSCs decreased angiogenesis in glioblastoma. The underlying mechanism may involve the down-regulation of PDGF-BB and IL1β secretion or decreases in FAK, VEGF or Akt [184, 185] . Another attractive source of MSCs, human endometrial mesenchymal stem cells (EnSCs), also show an ability to decrease tumor growth and to increase angiogenesis in ovarian cancer by inhibiting AKT phosphorylation and decreasing expression of VEGFA and HIF-1α, possibly via nuclear translocation of FoxO3a [186] .

hUCBMSCs are also reported to decrease glioblastoma cell invasion and migration by increasing PTEN or Mad1 expression and downregulating PI3K/AKT, c-Myc/ERK or EGFR/c-Met activities [187, 188] . Inhibition of Wnt signaling has been shown to decrease tumor growth and migration after treatment with hUCMSC-or hADMSC-CM in bile duct cancer and breast cancer, respectively [189, 190] .

Human BMMSC-secreted oncostatin M (OSM) has been reported to inhibit tumorigenicity and EMT by activating the OSM/STAT1 signaling pathway in lung adenocarcinoma cells [191] . Decreased cancer cell proliferation was also correlated with suppressed NF-κB expression and activity in HCCs and BCCs by MSCs derived from fetal bone marrow or fetal dermal tissue [192] . Vascular wall-resident MSCs as well as hBMMSCs displayed a capacity for decreasing the risk of lung metastasis after radiation-induced injury in breast cancer and melanoma by downregulating endothelial MMP2 and SASP factors CCL2 and Plau/uPA, which were induced by radiation injury [193] . In addition to suppressing tumor progression, hUCMSCs promote granulocytic differentiation of immature myeloid cancer cells in acute promyelocytic leukemia (APL), which drives the disease into remission by activating MEK/ERK pathways [194] .

Another promising strategy to treat progressive malignancy is the use of engineered MSCs, which show a remarkable ability to suppress tumor progression [195] . UCBMSCs with exogenous overexpression of CXCR1 and CXCR4 displayed enhanced tropism towards gliomas [196] . In addition, irradiation of glioma cells enhanced IL-8 expression, which promoted the tropism of hUCBM-SCs equipped with TRAIL migration to tumors, and further induced tumor cell apoptosis [197] . hBMMSCs overexpressing TRAIL can also induce apoptosis in CD133-positive primary glioma cells in vitro [198] . Modified interleukin-12 (IL-12p40N220Q; IL-12 M), which enhances expression of the IL-12p70 heterodimer that is necessary for induction of Th1 and CTL immunity, was overexpressed in hUCBMSCs and found to significantly decrease tumor growth and angiogenesis, as well as to increase the survival of glioma-bearing mice and to confer tumor-specific long-term T-cell immunity [199] .

In human glioma studies, IL-24-hUCMSCs promoted tumor cell apoptosis, and IFN-beta-hBMMSCs were Human bone marrow from Lonza

Human bone marrow of healthy donor

Inducing apoptosis in CD133-positive primary glioma cells Engineered TRAIL-expressing MSCs induced apoptosis of glioma cells [198] Human bone marrow of healthy donor

Engineered IFNβ-expressing MSCs [201] Human subcutaneous adipose tissue of 18-30 years old mothers receiving cesarean sections

Increased apoptosis; G0/G1 cell cycle arrest Upregulation of caspase-3 and caspase-9 and downregulation of survivin and XIAP [170] Human adipose tissue from liposuction

Paracrine effects by MSC-secreted cytokines [289] Human adipose tissue from patients receiving liposuctions (commercial)

Decreased tumor growth, migration; induced differentiation; no significant effect in survival Engineered BMP4-secreting MSCs had additional effect of improved survival [204] Human umbilical cords of 18-30 years old mothers receiving cesarean section

Increased apoptosis; G0/G1 cell cycle arrest Upregulation of caspase-3 and caspase-9 and downregulation of survivin and XIAP [170] Human umbilical cord of healthy donor CD73 CD105 CD90 CD45 CD34 CD14 CD11b HLA-DR Decreased cancer stem cell proliferation Direct cell interaction [290] Human umbilical cord from the cell library of the Chinese Academy of Science

Engineered IL-24-secreting MSCs induced tumor cell apoptosis [200] Human umbilical cord Wharton's jelly of healthy donor Human umbilical cord blood of healthy donors

Reduced the number of cyclin D1-positive cancer cells [174] Human umbilical cord blood of healthy donors

Decreased tumor growth and angiogenesis; increased the survival of glioma-bearing mice and tumor-specific long-term T-cell immunity Engineered IL-12 M-secreting MSCs [199] Human umbilical cord blood of healthy donors Not stated Enhanced tropism of MSCs towards tumor site Engineered CXCR4-overexpressing MSCs [196] Human umbilical cord blood from Medipost Co

Not stated

Engineered TRAIL-expressing MSCs induced apoptosis of glioma cells [197] Human umbilical cord blood of healthy donors Not stated Enhanced tropism of MSCs towards tumor site Engineered CXCR1-overexpressing MSCs [196] Lung cancer Human bone marrow of healthy donor

MSCs-secreted OSM activates OSM/STAT1 signaling pathway [191] Human subcutaneous adipose tissue of 18-30 years old mothers receiving cesarean sections

Increased apoptosis; G0/G1 cell cycle arrest Upregulation of caspase-3 and caspase-9 and downregulation of survivin and XIAP [170] Human umbilical cord of healthy donor

Cell cycle arrest; induced apoptosis; downregulated Bcl-2, pro-caspase-7, β-catenin and c-Myc [175] Human umbilical cords of 18-30 years old mothers receiving cesarean section

Increased apoptosis; G0/G1 cell cycle arrest Upregulation of caspase-3 and caspase-9 and downregulation of survivin and XIAP [170] Human umbilical cord Wharton's jelly

MSC-CM and in vivo co-transplantation [161] Human umbilical cord Wharton's jelly

Secretome has no effect on AC-A549 [291] Human umbilical cord Wharton's jelly

Decreased tumor cell growth and increased apoptosis Engineered IFNβ-expressing MSCs [202] Human endometrium of women with uterine fibroids

Not explored [191] 

Decreased NF-κB expression and activity [192] Human bone marrow of healthy donor

Engineered IFNβ-expressing MSCs induced cell cycle arrest and increasing expression of p21, p27 and FOXO3a as well as decreasing protein levels of cyclin D1, pRb and AKT [203] Human fetal dermal tissues at 4 months gestation from abortion (Z3)

Decreased NF-κB expression and activity [192] Human fetal dermal tissues at 4 months gestation from abortion (Z3)

Induced apoptosis and cell cycle arrest; Bcl-2, c-Myc, PCNA and survivin were downregulated [176] Human umbilical cord of healthy donor Human umbilical cords of 18-30 years old mothers receiving cesarean section

Increased apoptosis; G0/G1 cell cycle arrest Upregulation of caspase-3 and caspase-9 and downregulation of survivin and XIAP [170] Ovarian cancer Human bone marrow 

MSCs-CM induced reduction in the level of CA-125, LDH and beta-hCG and expression of MMP-2, MMP-9, and CA-125 as well as increased TIMP 1, 2, and 3 mRNA expression [177] Human umbilical cord Wharton's jelly of healthy donor

Decreased tumor cell growth and migration hWJSC-CL and hWJSC-CM induced apoptosis Upregulation of pro-apoptotic BAX and downregulation of anti-apoptotic BCL2 and SURVIVIN genes [167] Human umbilical cord Wharton's jelly

MSC-CM and MSC-CL decreased the expression of oncogenic cytokines, chemokines and growth factors in cancer cells [292] Human umbilical cord Wharton's jelly

Decreased tumor cells expression of CSC markers; increased cell cycle arrest and apoptosis MSC-CM and MSC-CL decreased expression of cell cycle regulatory genes (cyclin A2, Cyclin E1), prostaglandin receptor signaling genes (EP2, EP4) and the pro-inflammatory genes (IL-6, TNF-α) in cancer cells [178] Human umbilical cord Wharton's jelly

Not explored [293] Human umbilical cord Wharton's jelly

MSCs-CM induced reduction in the level of CA-125, LDH and beta-hCG and MMP-2, MMP-9, and CA-125 mRNA expression as well as increased TIMP 1, 2, and 3 mRNA expression [177] Human umbilical cord blood of healthy donors [193] Human adipose tissue from normal (nondiabetic) adult lipoaspiration

MSC-secreted conditioned medium inhibits canonical Wnt signalling [189] Human adipose tissue of individuals receiving mammoplasty

Not stated

Not explored [294] Human umbilical cord of healthy donors

MSCs secretome [295] Human umbilical cord Wharton's jelly of healthy donor 

Upregulating p21 Downregulating PCNA, cyclin D1, Bcl-2, Bcl-xL, and MMPs and upregulating p53 and p21 [168] Human umbilical cord Wharton's jelly of healthy donor Human umbilical cord Wharton's jelly of healthy donor

MSC-CL and MSC-CM induced apoptosis and autophagy [179] Gastric cancer Human umbilical cord blood

Engineered TNFSF14-secreting MSCs promote tumor cell apoptosis with elevated caspase-3 expression [209] Esophageal cancer

Human umbilical cord Wharton's jelly of healthy donor 

Not explored [297] Human umbilical cord of healthy donor

MSCs secreted IL-6 activates MEK/ERK pathways [194] Human umbilical cord of healthy donor

Not explored [297] Human Human umbilical cord Wharton's jelly of healthy donor

MSC-CM induced CD47 and PD-L1 expression decreased in the tumor cells [181] Human umbilical cord Wharton's jelly of healthy donor Human umbilical cord Wharton's jelly of healthy donor

IFNγ stimulated MSC secretome [298] Human umbilical cord blood of healthy donor

Decreased tumor cell proliferation Direct cell-to-cell contact caused arrest of the growth of cancer cells in the G0/G1 phase [183] shown to prolong animal survival [200, 201] . Meanwhile, IFN-beta-WJMSCs and IFN-beta-hBMMSCs exhibited the ability to suppress tumor growth in bronchioloalveolar carcinomas [202] and HCCs, respectively, the latter exerting its effect by increasing expression of p21, p27 and FOXO3a, as well as decreasing protein levels of cyclin D1, pRb and AKT [203] . In addition, engineered BMP4-secreting hADMSCs could suppress tumor cell migratory ability and increase survival in glioblastoma [204] . As for hematological cancers, treatment with hUC-MSCs equipped with Tandab (a tetravalent bispecific tandem diabody with two binding sites for CD3 and two for CD19) combined with IDO pathway inhibitor showed significantly decreased B cell lymphoma growth by way of decreasing CD98 and Jumonji, and by restoring the proliferation of T cells [205] . Another study demonstrated that UC-MSCs overexpressing IDO can inhibit proliferation of leukemia cells [206] . hWJMSCs engineered with scFvCD20-sTRAIL fusion protein, which targets CD20-positive cells and induces apoptosis through sTRAIL, inhibited proliferation in B cell lymphoma [207] . Another study showed that hWJMSCs transfected with vector coding sTRAIL driven by AFP promoter had significant antitumor activity in HCC [208] . Decreased tumor growth was also observed in gastric cancer and in epithelial ovarian cancer using hUCBMSCs delivering TNFSF14 or IL-21, respectively [209, 210] . In a syngeneic pancreatic tumor mouse model, IL15-hUCBMSCs inhibited tumor growth and increased survival of tumorbearing mice. The IL15-hUCBMSCs induced NK-and T-cell accumulation at the tumor site and established tumor-specific T-cell memory immunity [211] . Cytosine deaminase-expressing hADMSCs serving as a prodrug converting vehicle, showed significant decreases in colorectal cancer growth in the presence of prodrug 5-fluorocytosine [212] .

MSCs can contribute to tumor promotion as well as to tumor suppression. Although it may appear that these effects occur randomly, closer examination provides a more promising picture. Summarizing a total of 110 reports, (excluding engineered MSCs) reveals that in 58.6% of the studies, BMMSCs promoted tumor growth, while 9.8% of studies found that BMMSCs suppressed growth. Although the tendency of ADMSCs is not as obvious as that of BMMSCs, they also exhibit a preference for tumor promotion (Fig. 2) . In general, MSCs derived from reproduction-related sources, including placenta, umbilical cord, Wharton's jelly, and umbilical cord blood, show a higher likelihood for tumor suppression (Fig. 2) . In regards to tumor type, we found that BMMSCs show an overwhelming promoting effect on cancers of the bone (100%, 6/6), breast (100%, 7/7) and GI tract, (liver, bile duct, colorectal, gastric and esophageal; 93.75%, 15/16) (Fig. 2a) .

MSCs demonstrate an impressive suppressive ability in hematological cancers. In all 7 studies, MSCs from different tissue types showed tumor suppression. Similarly, in a total of 8 studies of MSCs and ovarian cancer, only one study reported that MSCs promoted tumor growth ( Fig. 2b) . To date, there is no report showing a tumor promoting effect for MSCs from placental tissue. MSCs can exert their effects directly by contacting tumor cells, or indirectly by secreting soluble factors and microRNAs that the affect the tumor cells. The mechanisms by which different types of MSCs promote or suppress the growth of different tumor types are complicated (Tables 2, 3, 5, Fig. 4) . Factors that may affect the properties of MSCs and cause different outcomes, include (1) the origin of the MSCs; (2) different processes of isolation, purification, and expansion of MSCs; and (3) different culture conditions and passages of the MSCs. Most of the results described herein were derived from direct or indirect in vitro co-culture systems or from in vivo co-injection experiments, but the underlying mechanisms were not always examined. It will be necessary to elucidate these underlying mechanisms, as well as to find potential biomarkers of MSC-tumor interactions for future clinical applications of MSCs.

In light of the tremendous potential of MSCs for treating various diseases, it is necessary to define the systemic distribution and to quantify the administered cells in order to facilitate our understanding of the safety and efficacy of MSC-based cell therapy. This information is critical in clinical trials since it is vitally important to know whether the transplanted cell products home to the target diseased sites to deliver their intended effects. Indeed, several factors can affect the pharmacokinetics (PK) of the administered MSCs, including cell size, cell source, immunological features and labeling, detection methods, route of administration, and size of the animal model.

The typical diameter of a MSC is between 15-30 μm; in comparison, lymphocytes have a diameter of only 4-12 μm [213] . Furthermore, MSCs become larger after serial ex vivo cell passaging [214] . The relatively large size of MSCs explains their initial mechanical entrapment at lung capillary systems after intravenous administration, a phenomenon referred to as the pulmonary first-pass effect [26, 215] . Redistribution to liver, spleen, and other inflamed tissues subsequently takes place in the following hours to days, with gradual clearance from the lungs [26] . In some studies, MSCs were still detected in the lungs up to 150 days after transplantation in vivo [216] . MSCs retained at the lungs potentially decrease the number of cells available for therapeutic effects [217] . To decrease the mechanical entrapment of MSCs at the lungs, several strategies may be implemented, including pretreatment with the vasodilator sodium nitroprusside in order to increase the effective diameter of the pulmonary capillary system; delivery via an extravascular route; or delivery via multiple smaller doses [215, 217, 218] . Although administering MSCs intra-arterially may decrease the extent of mechanical entrapment at the lungs [219] , the effect of cell size still has important implications, as larger MSCs may be associated with vascular occlusions that could cause subsequent ischemia and infarcts of unintended tissues and organs [220, 221] . Engineering of MSCs might potentially alter this adverse effect. For example, by overexpressing integrin α4 (ITGA4), which mediates leukocyte trafficking of MSCs, Cui et al. observed that cell aggregation of MSCs were significantly decreased, and MSC-associated cerebral embolism was ameliorated in rat model of stroke [222] . Furthermore, the risk of embolism has been found to be positively associated with cell dose of infusion and low infusion velocity [223] .

In addition, aging of either donor or recipient could affect the biodistribution of inoculated MSCs, with decreased transplantation efficiency observed with aged donor MSCs and recipients [224] . Furthermore, when MSCs were extracted from older donors, they exhibited lower proliferative and differentiation capabilities [225, 226] . The culture condition also plays a role in the kinetics of administered MSCs. For example, hypoxic preconditioning increased MSC migration to injured tissue via enhanced HGF/cMET signaling and MSC recruitment, thus affecting biodistribution of the administered cells [227] .

Immunogenic reactions also affect clearance and biodistribution of injected cells, as the allogeneic MSCs are not completely immune-privileged [228] . When MSCs are transplanted in an allogeneic host, the transplanted MSCs have decreased survival compared with their survival in a syngeneic host [229] . Formation of antibodies against injected MSCs could explain the reduced effectiveness and increased adverse effects that were observed with repeated inoculations in some studies [230] .

Furthermore, the injected cells can also trigger an instant blood-mediated inflammatory reaction (IBMIR), which causes reduced graft survival and thromboembolism [231] . A portion of injected MSCs do not reach their intended destination due to the host's immune reaction, embolization, and micro-ischemia [232] . Previous literature has demonstrated that the extent of IBMIR is related to the level of tissue factor (TF) expressed by MSCs; expression levels vary among different tissue origins of MSCs, and with culture conditions [233] . Compared with ADMSCs and UCMSCs, BMMSCs express lower levels of TF [233] . Thus, selecting TF-deficient BMMSCs may reduce the risk of IBMIR and improve the chances for clinical success. Otherwise, co-treatment with an anticoagulant may be an important consideration for clinical applications [234] .

A critical step in generating pharmacokinetic models of cell products is tracking the fate of cells following transplantation. An ideal quantification technique should have the following features: high sensitivity and specificity; long-term detection and monitoring; and spatiotemporal resolution. The advantages and disadvantages of currently available methods for quantitative MSC detection are summarized in Table 6 . Polymerase chain reaction (PCR) has been used to track human MSCs in murine xenogeneic models by detecting human DNA [19, [235] [236] [237] . The low limit of detection of quantitative PCR enables detection of 100 MSCs per gram of organ tissue, making it feasible to detect MSCs in patient biopsies. Both flow cytometry and optical imaging require labeling MSCs with fluorescent dyes or proteins. Flow cytometry enables estimation of the number of live MSCs per weight unit of tissue, and optical imaging uses a variety of dyes, such as 4′,6-diamidino-2-phenlindole (DAPI), that can bind reversibly or irreversibly to the MSCs [238] [239] [240] [241] . The use of red fluorescent protein (RFP) or green fluorescent protein (GFP) expressing MSCs has the advantage of providing viability information of transplanted cells [242] . However, the transfection efficiency is not consistent, and the transfected cells could have altered potency and expression and cannot be accurately tracked over time [243] . Therefore, the biodistribution and quantitative data produced by fluorescent protein labeling methods may be incomplete. Bioluminescence imaging (BLI) which utilizes luciferase reactions also has the advantage of providing viability information of transplanted cells, but this method suffers from poor tissue penetration and low spatial resolution. MSCs can also be labeled with gold nanoparticle and tracked by computed tomography (CT) image in vivo [244, 245] . These gold nanoparticles have advantage of exerting negligible influence on viability, proliferation, and differentiation ability of labeled MSCs, and offer good spatial resolution and long-term tracking when used in conjunction with CT modality [244] . However, sensitivity is relatively poor, and there is still difficulty deriving quantitative information from CT images [246] .

Magnetic resonance imaging (MRI) can be used to track MSCs in vivo by labeling MSCs with superparamagnetic iron oxide nanoparticles (SPIONs) or fluorine-19 ( 19 F). Direct labeling of MSCs with SPIONs is possible as these agents are readily taken up by MSCs and show up as hypointense signals on MRI [247] . However, some studies have shown that proliferative and differentiation capabilities of MSCs could be affected when labeled at higher concentrations [247] . The downside of SPION labeling is that the specificity of SPION-labeled cells could be low and the signals could be hard to differentiate from acutely injured tissues containing hemorrhages. In contrast, 19 F-labeling offers better specificity as endogenous fluorine level is low, minimizing background interference and is a better labeling agent when the targeting lesion involves hemorrhage [248] . In general, MRI offers good spatial resolution but suffers from poor temporal resolution. Positron emission tomography (PET), single-photon emission computed tomography (SPECT) [26, [249] [250] [251] and radioisotope labeling [26, 252, 253] have been used to image and track the migration dynamics, and inter-patient variability of MSCs in clinical patients, but quantifying cell numbers with these methods is difficult and only semi-quantitative information on the biodistribution of the transplanted cells can be obtained. Photoacoustic imaging, which combines ultrasonography with optical imaging, is another attractive approach, as ultrasonography has the unique advantage of providing real-time information while still maintaining good spatial resolution. By using gold nanorods coated with reactive oxygen species (ROS) sensitive dye as probe, Dhada et al. were able to also detect viability of implanted cells [254] . However, photoacoustic imaging suffers from operator dependent variability [255] . More recently, multimodal imaging probes that combine the advantage of different imaging modalities have been developed, including PET/MRI imaging agent [256] , SPECT/MRI/fluorescent imaging agent [257] , and SPECT/MRI/BLI imaging agent [258] .

An ideal cell tracking method should be biocompatible and nontoxic, require no genetic modification, have single-cell detection sensitivity, and permit quantification of cell numbers at any anatomic location. Optical imaging utilizing nanoparticles as exogenous contrast agents is suitable for this purpose, although the technique is mainly used for animal models in preclinical experimentation due to the limited penetration depth of visible photons into tissue. Among various exogenous contrast agents, fluorescent nanodiamond (FND) has emerged as an attractive option because it is chemically inert and inherently biocompatible [259, 260] . A viable application of FNDs for background-free imaging and quantitative tracking of MSCs in animal models beyond rodents has been demonstrated using magnetic modulation [261] [262] [263] . The magnetic modulation fluorescence (MMF) method uses magnets to modulate the fluorescence intensity of FNDs. This technique, which allows background-free imaging, together with the inertness of FNDs and the large quantity of the nanoparticles taken up by the cells, has permitted studies of the biodistribution and pharmacokinetics of FND-labeled MSCs in preclinical settings. This strategy can also be applied to the characterization of cell-based products in order to accelerate their progression towards commercialization to meet the needs of patients. The technique has excellent compatibility with time-gated fluorescence imaging, which has been shown to be a powerful means of acquiring high-contrast fluorescence imaging of FNDlabeled cells in tissues. The ability to find single cells is particularly valuable for ex vivo histological detection of MSCs in clinical trials. This combined approach represents an appealing alternative to hazardous radioisotope labeling techniques in cell tracking applications. The technique can be used with immune cells, stem cells, and other cell types used for cell therapy. Here, we put these technologies together, and describe how they could be used to contribute to the development of pharmacokinetic modeling of MSC-based cell products.

The ability to monitor the behavior of transplanted cells in vivo is required for cell therapy. When cellular products are submitted for investigational new drug (IND) status, pharmaceutical studies must provide evidence of not only the safety of the cell product, but also information regarding cell location, cell migration, PK and pharmacodynamics (PD), and cell biodistribution after transplantation in animal models. There are three critical issues that must be addressed for cell therapy: (1) whether therapeutic cells maintain their potency after transplantation, (2) the appropriate dosage for curing diseases and (3) a route of administration and a formulation that permits successful drug delivery. Over the past decade, the traditional concepts, confined to low molecular weight organic compounds and large biomolecules, have been challenged with the advent of new drugs based upon cells, which we refer to here as cell therapy. As for all drugs, understanding the pharmacology of cell-therapy products is critical for their effective application in the clinical setting. For example, tissue section and PCR does not provide sufficient information of cell behavior in vivo, because these procedures select a sample from a population, making it difficult to provide PK and PD information for the whole animal. In contrast, the FND-labelled tracking technique provides a new method to achieve high throughput whole organ treatment and analysis, providing accurate pharmacology information, such as PK, PD and biodistribution of the cellular therapy (Fig. 5a) . This method not only provides immediate and highly specific cell localization data after gathering histological sections from the animal, but also provides a one-step, one-tube analysis for any kind of animal tissue. Compared to the qPCR sampling method, this protocol can provide more accurate data for whole organ/tissue analysis and takes less time for validation and analysis.

We use a healthy mouse model to demonstrate that the FND-labelled platform can provide evidence of cell biodistribution. Figure 5b shows the biodistribution analysis of FND-labelled placenta choriodecidual membrane-derived MSCs (pcMSCs) for one week in a mouse model using the FND-based labelling platform. Our results show that the majority (up to 70%) of FNDlabelled pcMSCs localized to the lungs after intravenous administration, which is consistent with the pulmonary first-pass effect [217, 264] . The trapping of MSCs in the lungs is due to space restriction [265] , as pcMSCs are more than ~ 20 μm in diameter and much larger than the width of the micro-capillaries of the lung. After intravenous infusion, FND-labelled pcM-SCs disappeared from the lungs as time passed, and migrated to other tissues/organs such as the liver and spleen, or to injured sites. Nevertheless, the number of FND-labelled pcMSCs decreased in the heart and kidneys (Fig. 5b) .

As it has been reported that MSCs will migrate to injured sites [266] , we induced an ischemia-reperfusion injury to the left kidney in our animal model (Fig. 6a) and examined whether FND-labelled pcMSCs injected into the portal vein would appear in the injured kidney, to test the concept that MSCs will migrate to sites of injury. In our mouse model with healthy kidneys, the number of pcMSCs in the kidneys decreased over time (Fig. 6b, upper panel) and the decrease was evident in both the left and right kidneys. (Fig. 6b, lower panel) . In Fig. 6 Fluorescent nanodimond (FND)-labelled pcMSC biodistribution analysis in mouse model with a kidney ischemia-reperfusion injury. a Timeline of the ischemia-reperfusion kidney injury mouse model. The ischemia-reperfusion injury was created on the left-hand side kidney (L) in a mouse, then FND-labelled pcMSCs were injected through the portal vein. b Bodistribution of FND-labelled pcMSCs in healthy kidney mouse model. Experiments were repeated in triplicate and error bars represent the standard deviation of the measurements. c Biodistribution of FND-labelled pcMSCs in ischemia-reperfusion kidney injury mouse model. Experiments were repeated in triplicate and error bars represent the standard deviation of uncertainty. Data are presented as mean ± standard deviation. Data were analyzed using Student's t-test. *P value of < 0.05. **P value of < 0.01. ***P value of < 0.001. ****P value of < 0.0001 contrast, in the mouse model with the injury the number of FND-labelled pcMSCs in the injured kidney was highest on day 5 (3%; Fig. 6c ). As seen in the lower panel of Fig. 6c , the injured kidney (L kidney) had significantly more FND-labelled pcMSCs than the healthy kidney (R kidney). The percent of FND-labelled pcMSCs remained consistent over time (~ 0.25%) in the healthy right kidney (R kidney) (*P < 0.5, **P < 0.01, ***P < 0.001, ****P < 0.0001.) (Fig. 6c, lower panel) . Given these data, it appears that the percentage of MSCs that migrate to kidneys is limited to about 4%, and it appears that the kidneys have the ability to redistribute MSCs in vivo. In addition to providing fast and accurate results, this technique is completely safe to the cell tissue. The FND-labelling technique does not alter any properties of the cell, including cell viability, proliferation, differentiation and immunomodulation, making this method very biocompatible.

The potential and promise of MSC therapy is highly anticipated in recent and coming decades. As with all emerging new medical technologies, patient safety is always the first priority. As we have discussed, although the ability to modulate immune environment and promote tissue regeneration have been well reported in preclinical studies, the aspect regarding tumor induction or promotion is still one of the many concerns. The MSCs derived from different tissue origins or expanded under different culture conditions present different immune profiles which may result in tumor promotion [126] . Additionally, as the double sided blades of the MSCs' strong immune modulation ability [262] , evaluation of both the specific MSC properties as well as the patient's immune conditions is strongly needed. The patient's immune condition both before, during, and after treatment should be closely monitored.

Some reports showed that artificial engineering process may decrease the tumor induction and increase tumor-suppressing function of MSCs [263] . However, genetically engineered MSCs also raise other safety concerns. Although several clinical trials claimed the safety of MSC-treated patients, however, most of the trials only showed short-term safety and are without the examination of tumor-associated biomarkers [267, 268] .

A recent systematic review and meta-analysis reappraised 55 randomized controlled trials and over 2000 patients to investigate the safety of systemically inoculated MSCs [39] . The risk of fever was significantly greater in the group of patients receiving MSCs. There was no significant increase in the risk of infection, thrombo-embolic events, malignancy or ectopic tissue formation, while the risk of death was significantly lower in the MSC-treated patients. Among the included studies, severe adverse events, including treatment related fever, in-stent thrombosis with death, acute coronary artery occlusions after intra-coronary delivery, grade 1 anaphlyactoid reaction, gastric ulcer perforation, hypersensitivity reaction, and anal cancer, have been reported to be possibly related to MSC treatment. Although the conclusion of the meta-analysis ends on a promising note, it was also emphasized that an a priori plan to monitor safety should be outlined in every clinical study design, including immediate allergic reactions, local complications (hematoma formation, local infection), vascular obstructions (dyspnea, oliguria, myocardial infarction, venous thromboembolic events), systemic complications (systemic infection, abnormal liver or renal function), malignancy or ectopic manifestation of implanted MSCs, and other disease-specific safety considerations [39] .

Additionally, patients with medical history of ischemic diseases, cardiovascular diseases, lung fibrosis, concurrent neoplasm, and family history of hereditary cancer should be carefully reviewed during MSC treatment. The cell dose, infusion route and rate should be documented. The product profiles of the MSCs from different tissues and different generation processes, such as transcriptome, epigenome, proteomic data, cell populations, potential potency biomarkers, preclinical data from cell and animal studies, should be provided.

The therapeutic efficacy of MSCs in different disease indication is still under evaluation, as most of the studies to date have been limited to phase 1 and phase 2 studies ( Fig. 1b and 1c , Additional file 2). As we have discussed in this review, the differences in MSC tissue origins and the variety of cell culture conditions would be some of the important factors determining MSC potency in vivo [269] . Thus, the development of surrogate potency assays using preclinical animal model is needed [270] . Recently the International Society for Cellular Therapy (ISCT) have announced some strategies to identify the potential effective factors of MSC action mechanism, including the combined the matrix assay and multiple techniques, such as quantitative RNA analysis for the specific genes, flow cytometry analysis for cell surface markers, and the protein-based assay of secretome [271] . Potency assessments in evaluating cell pharmacology, cell delivery route, as well as the cell-drug interaction are still under development to improve the MSC precision therapy [272] [273] [274] [275] . Although the matrix assays were reported to serve as a platform to identify the biomarkers for MSC potency in vitro [276, 277] , whether this in vitro assays are able to identify the MSC potency are still under discussion. For example, the use of allogeneic human peripheral blood mononuclear cells for mixed lymphocyte reaction (MLR) assays is a popular assay to demonstrate the MSC immunomodulation capacity. However, the lack of robustness, accuracy, and reproducibility is of concern [278] [279] [280] . Additionally, the correlation between the in vitro assays and in vivo pre-clinical/clinical data requires further evaluation.

Cryopreservation could be another factor affecting MSC potency. It has been documented that the MSC cryostorge, the so-called "cryo stun effect", may decrease MSC therapeutic efficacy, leading to failures in MSC clinical trials [278] . Recently, a systematic review regarding the impact of cryopreservation on BMMSCs showed that the cryopreservation appears to affect the cell viability, apoptosis, cellular attachment, immunomodulation, and metabolism of BMMSCs [279] . Furthermore, these impaired viability or functions of the MSCs can be restored, partially or totally, by following an acclimation period [279] [280] [281] , or by IFNγ licensing before cryopreservation [282] .

In summary, the use of standardized potency assays should be incorporated into future MSC product release criteria. Thus, development of surrogate potency assays for different disease indications should be highlighted. The optimal process of cryopreservation and thawing may be another important factor requiring further attention.

MSCs are a major cornerstone to the advancement of cell therapy, yet much remains to be learned about their pharmacokinetics and pharmacodynamics after systemic application in vivo. The different tissue origins of MSCs not only confer different biological activities that affect their therapeutic usefulness, but also raise the concern of different safety profiles. Many methods, including herein discussed fluorescent nanodiamond, are available for tracking inoculated MSCs in vivo, each with different advantages and disadvantages. These imaging platforms will facilitate future studies to discern and optimize the use of different MSCs for future clinical therapies.

Endothelin-1; EVs: Extracellular vesicles; Exos: Exosomes; FAK: Focal adhesion kinase; FND: Fluorescent nanodiamond; FoxO3a: Forkhead box class O 3a; GBM: Glioblastoma Multiforme; Glut-1: Glucose transporter type 1; GROa: Growth-regulated oncogene-alpha (CXCL1); GSK3β: Glycogen synthase kinase 3β; hCG: Human chorionic gonadotropin; HDGF: Hepatoma-derived growth factor; HGF: Hepatocyte growth factor; HIF-1α: Hypoxia-inducible factor 1alpha; HK-2: Hexokinase-2; IBMIR: Instant blood-mediated inflammatory reaction

Interleukin 8; IFN: Interferon; JAK: Janus kinase; JNK: C-Jun N-terminal kinase; LDH: Lactic dehydrogenase; Mad1: Mitotic arrest deficient 1; MAPK: Mitogen-activated protein kinase; MARCKS: Myristoylated Alanine Rich Protein Kinase C Substrate

MMF: Magnetic modulation fluorescence; MMP: Matrix metalloproteinase

MSC: Mesenchymal stem/stromal cell; MWCO: Molecular weight cut off; NRG1: Neuregulin 1; NF-kB: Nuclear factor kappa-light-chain-enhancer of activated B cells; NK: Natural killer; OSM: Oncostatin M; PAI-1: Plasminogen activator inhibitor-1; PCNA: Proliferating cell nuclear antigen; PDCD4: Programmed cell death 4; PDGF: Platelet-derived growth factor; PDGFR: Platelet-derived growth factor receptor

PD: Pharmacodynamics; PK: Pharmacokinetics; PKM-2: Pyruvate Kinase M2

Urokinase-type plasminogen activator; pRb: Phosphorylated retinoblastoma protein; PTBP1: Polypyrimidine tract-binding protein 1; PTEN: Phosphatase and tensin homolog; RECK: Reversion-inducing-cysteine-rich protein with kazal motifs; SCC: Squamous cell carcinomas; SASP: Senescenceassociated secretory phenotype

Second mitochondria-derived activator of caspases; STAT : Signal transducer and activator of transcription; TAM: Tumorassociated macrophage; TF: Tissue factor; TGF-β: Transforming growth factor beta; Th1: T-helper 1; TIMP: Tissue inhibitors of metalloproteinase; TMZ: Temozolomide; TNF-α: Tumor Necrosis Factor-α; TNFSF14: Tumor necrosis factor superfamily member 14; TRAIL: Tumor necrosis factor-related apoptosis-inducing ligand; VEGF: Vascular endothelial growth factor

Biomanufacturing for clinically advanced cell therapies

Osteogenesis in transplants of bone marrow cells

Immunosuppression for in vivo research: state-of-the-art protocols and experimental approaches

Challenges for mesenchymal stromal cell therapies

Heterotopic of bone marrow. Analysis of precursor cells for osteogenic and hematopoietic tissues

Mesenchymal progenitor cells in human umbilical cord blood

Comparison of proliferative and multilineage differentiation potential of sheep mesenchymal stem cells derived from bone marrow, liver, and adipose tissue

Human placenta-derived cells have mesenchymal stem/progenitor cell potential

Postnatal human dental pulp stem cells (DPSCs) in vitro and in vivo

Co-expression of two perivascular cell markers isolates mesenchymal stem-like cells from human endometrium

Amniotic fluid as a novel source of mesenchymal stem cells for therapeutic transplantation

Human reserve pluripotent mesenchymal stem cells are present in the connective tissues of skeletal muscle and dermis derived from fetal, adult, and geriatric donors

Isolation and characterization of lung resident mesenchymal stem cells capable of differentiating into alveolar epithelial type II cells

Ex vivo expansion and subsequent infusion of human bone marrowderived stromal progenitor cells (mesenchymal progenitor cells): implications for therapeutic use

Transplantability and therapeutic effects of bone marrow-derived mesenchymal cells in children with osteogenesis imperfecta

Mesenchymal stem cells and acute lung injury

Use of bone mesenchymal stem cells to treat rats with acute liver failure

Bone marrow mesenchymal stem cells ameliorate rat acute renal failure by differentiation into renal tubular epithelial-like cells

Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease

Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells

Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graftversus-host disease: a phase II study

Autologous mesenchymal stem cells produce reverse remodelling in chronic ischaemic cardiomyopathy

Bone Marrow Mesenchymal Stem Cells (BM-MSCs) Improve Heart Function in Swine Myocardial Infarction Model through Paracrine Effects

Autologous transplantation of bone marrow cells improves damaged heart function

In vivo imaging to monitor differentiation and therapeutic effects of transplanted mesenchymal stem cells in myocardial infarction

In vivo tracking of 111In-oxine labeled mesenchymal stem cells following infusion in patients with advanced cirrhosis

Mesenchymal stem cells cooperate with bone marrow cells in therapy of diabetes

Early intervention with mesenchymal stem cells prevents nephropathy in diabetic rats by ameliorating the inflammatory microenvironment

In vivo tracking of stem cells in brain and spinal cord injury

Mesenchymal stem cells for spinal cord injury: current options, limitations, and future of cell therapy

Japan's approval of stem-cell treatment for spinal-cord injury concerns scientists

In vivo tracking and fate of intra-articularly injected superparamagnetic iron oxide particle-labeled multipotent stromal cells in an ovine model of osteoarthritis

Cartilage regeneration in humans with adipose tissue-derived stem cells and adipose stromal vascular fraction cells: updated status

Current therapeutic strategies for stem cellbased cartilage regeneration

Enhancement of chondrogenesis of adipose-derived stem cells in HA-PNIPAAm-CL hydrogel for cartilage regeneration in rabbits

Intra-articularly injected mesenchymal stem cells promote cartilage regeneration, but do not permanently engraft in distant organs

Targeted transplantation of iron oxide-labeled, adipose-derived mesenchymal stem cells in promoting meniscus regeneration following a rabbit massive meniscal defect

COVID-19: towards controlling of a pandemic

Cell therapy with intravascular administration of mesenchymal stromal cells continues to appear safe: An updated systematic review and meta-analysis. EClinMed

Mesenchymal stem cells: building blocks for molecular medicine in the 21st century

Mesenchymal stem cells directly interact with breast cancer cells and promote tumor cell growth in vitro and in vivo

Directed fusion of mesenchymal stem cells with cardiomyocytes via VSV-G facilitates stem cell programming

Multipotent human stromal cells improve cardiac function after myocardial infarction in mice without long-term engraftment

Intravenous hMSCs improve myocardial infarction in mice because cells embolized in lung are activated to secrete the anti-inflammatory protein TSG-6

Miro1 enhances mitochondria transfer from multipotent mesenchymal stem Cells (MMSC) to neural cells and improves the efficacy of cell recovery

Exosome derived from human umbilical cord mesenchymal stem cell mediates MiR-181c attenuating burn-induced excessive inflammation

Paracrine mechanisms of mesenchymal stem cells in tissue repair

Mesenchymal stem cell-derived interleukin 1 receptor antagonist promotes macrophage polarization and inhibits B cell differentiation

Multipotent stromal cells skew monocytes towards an anti-inflammatory interleukin-10-producing phenotype by production of interleukin-6

VEGF/SDF-1 promotes cardiac stem cell mobilization and myocardial repair in the infarcted heart

Mesenchymal stem cell-conditioned medium facilitates angiogenesis and fracture healing in diabetic rats

Bone marrow concentrate-induced mesenchymal stem cell conditioned medium facilitates wound healing and prevents hypertrophic scar formation in a rabbit ear model

Human umbilical cord-derived mesenchymal stem cells conditioned medium attenuate interstitial fibrosis and stimulate the repair of tubular epithelial cells in an irreversible model of unilateral ureteral obstruction

The membrane mesenchymal stem cell derived conditioned medium exerts neuroprotection against focal cerebral ischemia by targeting apoptosis

Multiple paracrine factors secreted by mesenchymal stem cells contribute to angiogenesis

Comparative transcriptomic analysis of human mesenchymal stem cells derived from dental pulp and adipose tissues

Heterogeneity of proangiogenic features in mesenchymal stem cells derived from bone marrow, adipose tissue, umbilical cord, and placenta

Short-term preconditioning enhances the therapeutic potential of adipose-derived stromal/stem cell-conditioned medium in cisplatininduced acute kidney injury

IL-17A improves the efficacy of mesenchymal stem cells in ischemic-reperfusion renal injury by increasing Treg percentages by the COX-2/PGE2 pathway

Long-term complications, immunologic effects, and role of passage for outcome in mesenchymal stromal cell therapy

Comparison of biological properties of umbilical cord-derived mesenchymal stem cells from early and late passages: immunomodulatory ability is enhanced in aged cells

Selection of optimal passage of bone marrow-derived mesenchymal stem cells for stem cell therapy in patients with amyotrophic lateral sclerosis

3D spheroid culture enhances survival and therapeutic capacities of MSCs injected into ischemic kidney

Expression of proinflammatory cytokines by human mesenchymal stem cells in response to cyclic tensile strain

The potential use of stem cells in multiple sclerosis: An overview of the preclinical experience

Umbilical cord mesenchymal stem cell treatment for Crohn's disease: a randomized controlled clinical trial

Small hypoxia-primed mesenchymal stem cells attenuate graft-versus-host disease

Mesenchymal stem cells: a trump card for the treatment of diabetes?

Mesenchymal stem cells reduce colitis in mice via release of TSG6, independently of their localization to the intestine

Mesenchymal stem cells attenuate cisplatininduced nephrotoxicity in iNOS-dependent manner

The role of TNF-alpha induced MSCs on suppressive inflammation by increasing TGF-beta and IL-10. Open Access Maced

Proinflammatory stimuli induce galectin-9 in human mesenchymal stromal cells to suppress T-cell proliferation

Bone marrow stromal cells attenuate sepsis via prostaglandin E(2)-dependent reprogramming of host macrophages to increase their interleukin-10 production

Anti-inflammatory protein TSG-6 secreted by activated MSCs attenuates zymosaninduced mouse peritonitis by decreasing TLR2/NF-kappaB signaling in resident macrophages

Mesenchymal stromal cells induce peculiar alternatively activated macrophages capable of dampening both innate and adaptive immune responses

Crosstalk between mesenchymal stem cells and T regulatory cells is crucially important for the attenuation of acute liver injury

Fibroblast growth factor-1 is a mesenchymal stromal cell-secreted factor stimulating proliferation of osteoarthritic chondrocytes in co-culture

Insulin-like growth factor-1 sustains stem cell mediated renal repair

Paracrine action enhances the effects of autologous mesenchymal stem cell transplantation on vascular regeneration in rat model of myocardial infarction

Secreted frizzled-related protein-1 enhances mesenchymal stem cell function in angiogenesis and contributes to neovessel maturation

Secreted frizzled related protein 2 (Sfrp2) is the key Akt-mesenchymal stem cell-released paracrine factor mediating myocardial survival and repair

Vasculotropic, paracrine actions of infused mesenchymal stem cells are important to the recovery from acute kidney injury

Novel non-angiogenic role for mesenchymal stem cell-derived vascular endothelial growth factor on keratinocytes during wound healing

Targeted migration of bone marrow mesenchymal stem cells inhibits silica-induced pulmonary fibrosis in rats

Mesenchymal stem cells attenuate liver fibrosis by suppressing Th17 cells -an experimental study

Microencapsulated human mesenchymal stem cells decrease liver fibrosis in mice

Paracrine factors from mesenchymal stem cells attenuate epithelial injury and lung fibrosis

Bone marrow mesenchymal stem cells attenuate silica-induced pulmonary fibrosis via paracrine mechanisms

Mesenchymal stem cells correct inappropriate epithelial-mesenchyme relation in pulmonary fibrosis using stanniocalcin-1

Effects of mesenchymal stem cell transplantation on extracellular matrix after myocardial infarction in rats

Mitochondria in health and diseases

Mitochondrial transfer from Wharton's jelly-derived mesenchymal stem cells to mitochondria-defective cells recaptures impaired mitochondrial function

Cutting edge: Membrane nanotubes in vivo: a feature of MHC class II+ cells in the mouse cornea

Mesenchymal stem cells rescue injured endothelial cells in an in vitro ischemia-reperfusion model via tunneling nanotube like structure-mediated mitochondrial transfer

Mitochondrial transfer from bone-marrow-derived stromal cells to pulmonary alveoli protects against acute lung injury

Mitochondrial transfer of induced pluripotent stem cell-derived mesenchymal stem cells to airway epithelial cells attenuates cigarette smoke-induced damage

Miro1 regulates intercellular mitochondrial transport & enhances mesenchymal stem cell rescue efficacy

NADPH oxidase-2 derived superoxide drives mitochondrial transfer from bone marrow stromal cells to leukemic blasts

Cell adhesion-mediated mitochondria transfer contributes to mesenchymal stem cell-induced chemoresistance on T cell acute lymphoblastic leukemia cells

Protective mitochondrial transfer from bone marrow stromal cells to acute myeloid leukemic cells during chemotherapy

Extracellular vesicles: a new communication paradigm?

Effects of mesenchymal stem cell-derived exosomes on experimental autoimmune uveitis

Therapeutic effects of mesenchymal stem cell-derived exosomes on retinal detachment

Bone marrow mesenchymal stem cell-derived exosomes protect against myocardial infarction by promoting autophagy

Immunomodulatory effects of mesenchymal stem cell-derived exosomes on experimental type-1 autoimmune diabetes

Promising effects of exosomes isolated from menstrual blood-derived mesenchymal stem cell on wound-healing process in diabetic mouse model

Mesenchymal stem cell-derived exosomes promote fracture healing in a mouse model

Exosomes secreted by stem cells from human exfoliated deciduous teeth contribute to functional recovery after traumatic brain injury by shifting microglia M1/M2 polarization in rats

hucMSC derived exosomes promote functional recovery in spinal cord injury mice via attenuating inflammation

A systematic review of preclinical studies on the therapeutic potential of mesenchymal stromal cell-derived microvesicles

Immunomodulatory effects of mesenchymal stromal cells-derived exosome

Immunosuppressive effect of mesenchymal stem cell-derived exosomes on a concanavalin A-induced liver injury model

Human umbilical cord mesenchymal stem cell exosomes enhance angiogenesis through the Wnt4/β-catenin pathway

Mesenchymal stem cell exosomes induce proliferation and migration of normal and chronic wound fibroblasts, and enhance angiogenesis in vitro

Circulating apoptotic bodies maintain mesenchymal stem cell homeostasis and ameliorate osteopenia via transferring multiple cellular factors

Donor MSCs release apoptotic bodies to improve myocardial infarction via autophagy regulation in recipient cells

Immunoregulatory impact of human mesenchymal-conditioned media and mesenchymal derived exosomes on monocytes

Biodistribution of mesenchymal stem cell-derived extracellular vesicles in a radiation injury bone marrow murine model

Application of mesenchymal stem cell-derived extracellular vesicles for stroke: biodistribution and MicroRNA study

Effects of mesenchymal stem cells on solid tumor metastasis in experimental cancer models: a systematic review and meta-analysis

Chronic niche inflammation in endometriosis-associated infertility: current understanding and future therapeutic strategies

Application of mesenchymal stem cells for therapeutic agent delivery in anti-tumor treatment

Bone marrow mesenchymal stem cells increase motility of prostate cancer cells via production of stromal cell-derived factor-1alpha

Mesenchymal stromal cells may enhance metastasis of neuroblastoma via SDF-1/CXCR4 and SDF-1/ CXCR7 signaling

Exosomes from glioma cells induce a tumor-like phenotype in mesenchymal stem cells by activating glycolysis

Extracellular vesicles secreted by hypoxia pre-challenged mesenchymal stem cells promote non-small cell lung cancer cell growth and mobility as well as macrophage M2 polarization via miR-21-5p delivery

A novel antagonist of CXCR4 prevents bone marrow-derived mesenchymal stem cell-mediated osteosarcoma and hepatocellular carcinoma cell migration and invasion

Human mesenchymal stem cells promote tumor growth via MAPK pathway and metastasis by epithelial mesenchymal transition and integrin α5 in hepatocellular carcinoma

Mesenchymal stem cells enhance growth and metastasis of colon cancer

Stroma-directed imatinib therapy impairs the tumorpromoting effect of bone marrow-derived mesenchymal stem cells in an orthotopic transplantation model of colon cancer

Helicobacter pylori infection-induced hepatoma-derived growth factor regulates the differentiation of human mesenchymal stem cells to myofibroblast-like cells

Mesenchymal stem cells promote formation of colorectal tumors in mice

Mesenchymal stem cells promote growth and angiogenesis of tumors in mice

Impact of mesenchymal stem cell secreted PAI-1 on colon cancer cell migration and proliferation

Bone marrow-derived mesenchymal stem cells promote colorectal cancer progression through paracrine neuregulin 1/HER3 signalling

Suppression of PTBP1 signaling is responsible for mesenchymal stem cell induced invasion of low malignancy cancer cells

Human MSCs promotes colorectal cancer epithelial-mesenchymal transition and progression via CCL5/beta-catenin/Slug pathway

Exosomes derived from human bone marrow mesenchymal stem cells promote tumor growth through hedgehog signaling pathway

STAT3 activation by IL-6 from mesenchymal stem cells promotes the proliferation and metastasis of osteosarcoma

Interaction between human osteosarcoma and mesenchymal stem cells via an interleukin-8 signaling loop in the tumor microenvironment

Bone marrow-derived mesenchymal stem cells promote invasiveness and transendothelial migration of osteosarcoma cells via a mesenchymal to amoeboid transition

Mesenchymal stem cells within tumour stroma promote breast cancer metastasis

Hypoxia-inducible factor-dependent signaling between triple-negative breast cancer cells and mesenchymal stem cells promotes macrophage recruitment

Tumor-stroma-inflammation networks promote pro-metastatic chemokines and aggressiveness characteristics in triplenegative breast cancer

Exosomes from bone marrow mesenchymal stem cells contain a microRNA that promotes dormancy in metastatic breast cancer cells

Induction of ALP and MMP9 activity facilitates invasive behavior in heterogeneous human BMSC and HNSCC 3D spheroids

Gremlin1 delivered by mesenchymal stromal cells promoted epithelial-mesenchymal transition in human esophageal squamous cell carcinoma

Umbilical cord blood-derived mesenchymal stem cells inhibit, but adipose tissue-derived mesenchymal stem cells promote, glioblastoma multiforme proliferation

Adipose-derived stem cells induced EMT-like changes in H358 lung cancer cells

Human adiposederived mesenchymal stem cell-secreted CXCL1 and CXCL8 facilitate breast tumor growth by promoting angiogenesis

Influence of mesenchymal stem cells conditioned media on proliferation of urinary tract cancer cell Lines and their sensitivity to ciprofloxacin

Adipose-derived mesenchymal stem cells promote cell proliferation and invasion of epithelial ovarian cancer

The pro-inflammatory peptide LL-37 promotes ovarian tumor progression through recruitment of multipotent mesenchymal stromal cells

Mesenchymal stem cells derived from human adipose tissues favor tumor cell growth in vivo

Exosomes from human adipose-derived mesenchymal stem cells promote migration through Wnt signaling pathway in a breast cancer cell model

Mesenchymal stem cell-induced doxorubicin resistance in triple negative breast cancer

Umbilical cord-derived mesenchymal stem cells promote proliferation and migration in MCF-7 and MDA-MB-231 breast cancer cells through activation of the ERK pathway

Human umbilical cord mesenchymal stem cell-derived extracellular vesicles promote lung adenocarcinoma growth by transferring miR-410

Knockdown of TGF-beta1 expression in human umbilical cord mesenchymal stem cells reverts their exosome-mediated EMT promoting effect on lung cancer cells

Tropism of mesenchymal stem cell toward CD133(+) stem cell of glioblastoma in vitro and promote tumor proliferation in vivo

Wharton's jelly mesenchymal stromal cells have contrasting effects on proliferation and phenotype of cancer stem cells from different subtypes of lung cancer

Impact of mesenchymal stem cells' secretome on glioblastoma pathophysiology

Microvesicles derived from human Wharton's jelly mesenchymal stem cells promote human renal cancer cell growth and aggressiveness through induction of hepatocyte growth factor

Ten Dijke P. TGF-β-mediated epithelial-mesenchymal transition and cancer metastasis

Human mesenchymal stem cells inhibit metastasis of a hepatocellular carcinoma model using the MHCC97-H cell line

Extracellular vesicles-mediated noncoding RNAs transfer in cancer

Human umbilical cord Wharton's jelly stem cell (hWJSC) extracts inhibit cancer cell growth in vitro

Wharton's jelly-derived mesenchymal stromal cells and fibroblast-derived extracellular matrix synergistically activate apoptosis in a p21-dependent mechanism in WHCO1 and MDA MB 231 cancer cells in vitro

Rat umbilical cord stem cells completely abolish rat mammary carcinomas with no evidence of metastasis or recurrence 100 days post-tumor cell inoculation

Conditioned media from human adipose tissue-derived mesenchymal stem cells and umbilical cord-derived mesenchymal stem cells efficiently induced the apoptosis and differentiation in human glioma cell lines in vitro

Paracrine effects of mesenchymal stem cells induce senescence and differentiation of glioblastoma stem-like cells

Regulation of glioblastoma progression by cord blood stem cells is mediated by downregulation of cyclin D1

Cord blood stem cell-mediated induction of apoptosis in glioma downregulates X-linked inhibitor of apoptosis protein (XIAP)

Human umbilical cord blood-derived mesenchymal stem cells inhibit C6 glioma via downregulation of cyclin D1

Suppression of tumor cell proliferation and migration by human umbilical cord mesenchymal stem cells: a possible role for apoptosis and Wnt signaling

Suppression of tumorigenesis by human mesenchymal stem cells in a hepatoma model

Antiproliferative effects of mesenchymal stem cells (MSCs) derived from multiple sources on ovarian cancer cell lines: an in-vitro experimental study

Human Wharton's jelly stem cell (hWJSC) extracts inhibit ovarian cancer cell lines OVCAR3 and SKOV3 in vitro by inducing cell cycle arrest and apoptosis

Human Wharton's jelly stem cell conditioned medium and cell-free lysate inhibit human osteosarcoma and mammary carcinoma cell growth in vitro and in xenograft mice

Microvesicles derived from human umbilical cord Wharton's jelly mesenchymal stem cells attenuate bladder tumor cell growth in vitro and in vivo

Induction of immunogenic cell death in lymphoma cells by Wharton's jelly mesenchymal stem cell conditioned medium

Human umbilical cord Wharton's jelly stem cell conditioned medium induces tumoricidal effects on lymphoma cells through hydrogen peroxide mediation

Human umbilical cord blood-derived mesenchymal stem cells (hUCB-MSC) inhibit the proliferation of K562 (human erythromyeloblastoid leukaemic cell line)

Human bone marrow-derived mesenchymal stem cells suppress human glioma growth through inhibition of angiogenesis

Downregulation of Focal Adhesion Kinase (FAK) by cord blood stem cells inhibits angiogenesis in glioblastoma

Human endometrial mesenchymal stem cells exhibit intrinsic anti-tumor properties on human epithelial ovarian cancer cells

Upregulation of PTEN in glioma cells by cord blood mesenchymal stem cells inhibits migration via downregulation of the PI3K/Akt pathway

Transcriptional repression of Mad-Max complex by human umbilical cord blood stem cells downregulates extracellular signal-regulated kinase in glioblastoma

The inhibitory influence of adipose tissue-derived mesenchymal stem cell environment and Wnt antagonism on breast tumour cell lines

Suppression of cholangiocarcinoma cell growth by human umbilical cord mesenchymal stem cells: a possible role of Wnt and Akt signaling

Oncostatin m modulates the mesenchymal-epithelial transition of lung adenocarcinoma cells by a mesenchymal stem cell-mediated paracrine effect

NF-kappaB downregulation may be involved the depression of tumor cell proliferation mediated by human mesenchymal stem cells

Therapy with multipotent mesenchymal stromal cells protects lungs from radiation-induced injury and reduces the risk of lung metastasis

Mesenchymal stem cells induce granulocytic differentiation of acute promyelocytic leukemic cells via IL-6 and MEK/ERK pathways

Genetically modified mesenchymal stromal cells in cancer therapy

CXCR4-transfected human umbilical cord blood-derived mesenchymal stem cells exhibit enhanced migratory capacity toward gliomas

Irradiation enhances the tumor tropism and therapeutic potential of tumor necrosis factor-related apoptosis-inducing ligand-secreting human umbilical cord blood-derived mesenchymal stem cells in glioma therapy

Assessment of therapeutic efficacy and fate of engineered human mesenchymal stem cells for cancer therapy

Gene therapy of intracranial glioma using interleukin 12-secreting human umbilical cord blood-derived mesenchymal stem cells

Umbilical cord-derived mesenchymal stromal/stem cells expressing IL-24 induce apoptosis in gliomas

Human bone marrow-derived mesenchymal stem cells in the treatment of gliomas

Human umbilical cord matrix-derived stem cells expressing interferon-beta gene significantly attenuate bronchioloalveolar carcinoma xenografts in SCID mice

Interferon-beta gene-modified human bone marrow mesenchymal stem cells attenuate hepatocellular carcinoma through inhibiting AKT/FOXO3a pathway

Mesenchymal stem cells from human fat engineered to secrete BMP4 are nononcogenic, suppress brain cancer, and prolong survival

Mesenchymal stromal cells as vehicles of tetravalent bispecific Tandab (CD3/CD19) for the treatment of B cell lymphoma combined with IDO pathway inhibitor D-1-methyl-tryptophan

Forced expression of indoleamine-2,3-dioxygenase in human umbilical cord-derived mesenchymal stem cells abolishes their anti-apoptotic effect on leukemia cell lines in vitro

Human umbilical cord mesenchymal stem cells as vehicles of CD20-specific TRAIL fusion protein delivery: a double-target therapy against non-Hodgkin's lymphoma

Suppression of orthotopically implanted hepatocarcinoma in mice by umbilical cord-derived mesenchymal stem cells with sTRAIL gene expression driven by AFP promoter

Gene therapy of gastric cancer using LIGHT-secreting human umbilical cord blood-derived mesenchymal stem cells

Human umbilical blood mononuclear cell-derived mesenchymal stem cells serve as interleukin-21 gene delivery vehicles for epithelial ovarian cancer therapy in nude mice

Human umbilical cord blood-derived mesenchymal stem cells producing IL15 eradicate established pancreatic tumor in syngeneic mice

Adipose tissue-derived human mesenchymal stem cells mediated prodrug cancer gene therapy

Concise review: mesenchymal stem cell-based drug delivery: The good, the bad, the ugly, and the promise

Automated image analysis detects aging in clinical-grade mesenchymal stromal cell cultures

The dynamic in vivo distribution of bone marrow-derived mesenchymal stem cells after infusion

The fate of mesenchymal stem cells transplanted into immunocompetent neonatal mice: implications for skeletal gene therapy via stem cells

Pulmonary passage is a major obstacle for intravenous stem cell delivery: the pulmonary first-pass effect

Stem cell transplantation: the lung barrier

MSCs: Delivery routes and engraftment, cell-targeting strategies, and immune modulation

The size of mesenchymal stem cells is a significant cause of vascular obstructions and stroke

Intraarterial route increases the risk of cerebral lesions after mesenchymal cell administration in animal model of ischemia

Integrin α4 overexpression on rat mesenchymal stem cells enhances transmigration and reduces cerebral embolism after intracarotid injection

The cerebral embolism evoked by intra-arterial delivery of allogeneic bone marrow mesenchymal stem cells in rats is related to cell dose and infusion velocity

Distribution pattern following systemic mesenchymal stem cell injection depends on the age of the recipient and neuronal health

Age-related intrinsic changes in human bone-marrow-derived mesenchymal stem cells and their differentiation to osteoblasts

Donor age negatively impacts adipose tissue-derived mesenchymal stem cell expansion and differentiation

Hypoxic preconditioning results in increased motility and improved therapeutic potential of human mesenchymal stem cells

Immunoprivileged no more: measuring the immunogenicity of allogeneic adult mesenchymal stem cells

Direct imaging of immune rejection and memory induction by allogeneic mesenchymal stromal cells

Repeated intra-articular injection of allogeneic mesenchymal stem cells causes an adverse response compared to autologous cells in the equine model

Intravascular mesenchymal stromal/stem cell therapy product diversification: time for new clinical guidelines

Fate of cultureexpanded mesenchymal stem cells in the microvasculature: in vivo observations of cell kinetics

Selection of tissue factor-deficient cell transplants as a novel strategy for improving hemocompatibility of human bone marrow stromal cells

Thromboembolism induced by umbilical cord mesenchymal stem cell infusion: a report of two cases and literature review

Rapid hematopoietic recovery after coinfusion of autologousblood stem cells and culture-expanded marrow mesenchymal stem cells in advanced breast cancer patients receiving high-dose chemotherapy

In vivo distribution of human adipose-derived mesenchymal stem cells in novel xenotransplantation models

Long-term detection of human adipose-derived mesenchymal stem cells after intraarticular injection in SCID mice

A physiologically based kinetic model for elucidating the in vivo distribution of administered mesenchymal stem cells

Noninvasive cell-tracking methods

Biodistribution of mesenchymal stem cell-derived extracellular vesicles in a model of acute kidney injury monitored by optical imaging

In vivo human adiposederived mesenchymal stem cell tracking after intra-articular delivery in a rat osteoarthritis model

Generation of transgenic mesenchymal stem cells expressing green fluorescent protein as reporter gene using no viral vector in caprine

Cellular GFP toxicity and immunogenicity: potential confounders in in vivo cell tracking experiments

Long-term in vivo CT tracking of mesenchymal stem cells labeled with Au@BSA@PLL nanotracers

CT/NIRF dualmodal imaging tracking and therapeutic efficacy of transplanted mesenchymal stem cells labeled with Au nanoparticles in silica-induced pulmonary fibrosis

Accomplishments and challenges in stem cell imaging in vivo

Magnetic resonance imaging of umbilical cord stem cells labeled with superparamagnetic iron oxide nanoparticles: effects of labelling and transplantation parameters

Transplanted adipose-derived stem cells can be short-lived yet accelerate healing of acid-burn skin wounds: a multimodal imaging study

Stem cell imaging: from bench to bedside

Transplantation and tracking of human-induced pluripotent stem cells in a pig model of myocardial infarction: assessment of cell survival, engraftment, and distribution by hybrid single photon emission computed tomography/computed tomography of sodium iodide symporter transgene expression

111In oxine labelled mesenchymal stem cell SPECT after intravenous administration in myocardial infarction

Lung delivery of MSCs expressing anti-cancer protein TRAIL visualised with (89)Zr-oxine PET-CT

Clinical tracking of cell transfer and cell transplantation: trials and tribulations

In vivo photoacoustic tracking of mesenchymal stem cell viability

Real-time imaging tracking of mesenchymal stem cells labeled with lipid-poly(lactic-co-glycolic acid) nanobubbles

PET/MRI dual-modality tumor imaging using arginine-glycine-aspartic (RGD)-conjugated radiolabeled iron oxide nanoparticles

MRI/SPECT/fluorescent tri-modal probe for evaluating the homing and therapeutic efficacy of transplanted mesenchymal stem cells in a rat ischemic stroke model

Multi-modal imaging probe for assessing the efficiency of stem cell delivery to orthotopic breast tumours

Intracellular delivery of luciferase with fluorescent nanodiamonds for dual-modality imaging of human stem cells

The biocompatibility of fluorescent nanodiamonds and their mechanism of cellular uptake

Tracking the engraftment and regenerative capabilities of transplanted lung stem cells using fluorescent nanodiamonds

Fluorescent nanodiamonds enable quantitative tracking of human mesenchymal stem cells in miniature pigs

Fluorescent nanodiamonds enable long-term detection of human adipose-derived stem/stromal cells in an in vivo chondrogenesis model using decellularized extracellular matrices and fibrin glue polymer

The pulmonary first-pass effect, xenotransplantation and translation to clinical trials-a commentary

Human adipose tissue-derived mesenchymal stem cells induce explosive T-cell proliferation

Mesenchymal stem cells home to injured tissues when co-infused with hematopoietic cells to treat a radiation-induced multi-organ failure syndrome

Autologous mesenchymal stromal cells embedded in tricalcium phosphate for posterolateral spinal fusion: results of a prospective phase I/II clinical trial with long-term follow-up

Trends in mesenchymal stem cell clinical trials 2004-2018: Is efficacy optimal in a narrow dose range?

Tolerance to bone marrow transplantation: do mesenchymal stromal cells still have a future for acute or chronic GvHD?

Stem cells as an emerging paradigm in stroke 4: advancing and accelerating preclinical research

International Society for Cellular Therapy perspective on immune functional assays for mesenchymal stromal cells as potency release criterion for advanced phase clinical trials

Mesenchymal stromal cell therapeutic delivery: translational challenges to clinical application

Clinical parameters affecting multipotent adult progenitor cells in vitro

Mesenchymal stromal cell therapeutic potency is dependent upon viability, route of delivery, and immune match

Thawed mesenchymal stem cell product shows comparable immunomodulatory potency to cultured cells in vitro and in polymicrobial septic animals

Potency analysis of mesenchymal stromal cells using a combinatorial assay matrix approach

Development of a surrogate angiogenic potency assay for clinicalgrade stem cell production

Characterization of mesenchymal stromal cells: potency assay development

The challenge of defining mesenchymal stromal cell potency assays and their potential use as release criteria

A reproducible immunopotency assay to measure mesenchymal stromal cell-mediated T-cell suppression

Differential effects of extracellular vesicles secreted by mesenchymal stem cells from different sources on glioblastoma cells

Conditioned medium from adipose-derived stem cells (ADSCs) promotes epithelialto-mesenchymal-like transition (EMT-Like) in glioma cells in vitro

Omental adipose tissue-derived stromal cells promote vascularization and growth of endometrial tumors

Mesenchymal stem cells mediate the clinical phenotype of inflammatory breast cancer in a preclinical model

Human adipose-derived mesenchymal stromal cells may promote breast cancer progression and metastatic spread

Mesenchymal stem cells regulate melanoma cancer cells extravasation to bone and liver at their perivascular niche

Mesenchymal stem cells increase proliferation but do not change quiescent state of osteosarcoma cells: potential implications according to the tumor resection status

Tumor cell behaviour modulation by mesenchymal stromal cells

Different effects of human umbilical cord mesenchymal stem cells on glioblastoma stem cells by direct cell interaction or via released soluble factors

Effect of human Wharton's jelly mesenchymal stem cell secretome on proliferation, apoptosis and drug resistance of lung cancer cells

Cytokines secreted by human Wharton's jelly stem cells inhibit the proliferation of ovarian cancer (OVCAR3) cells in vitro

Primary ovarian cancer cell inhibition by human Wharton's Jelly stem cells (hWJSCs): mapping probable mechanisms and targets using systems oncology

Therapeutic potential of mesenchymal stromal cells in a mouse breast cancer metastasis model

An anticancer effect of umbilical cord-derived mesenchymal stem cell secretome on the breast cancer cell line

Human umbilical cord blood mesenchymal stem cell-derived extracellular matrix prohibits metastatic cancer cell MDA-MB-231 proliferation

A peculiar molecular profile of umbilical cord-mesenchymal stromal cells drives their inhibitory effects on multiple myeloma cell growth and tumor progression

Human Wharton's jelly mesenchymal stem cell secretome display antiproliferative effect on leukemia cell line and produce additive cytotoxic effect in combination with doxorubicin

Magnetic resonance imaging tracking and assessing repair function of the bone marrow mesenchymal stem cells transplantation in a rat model of spinal cord injury

Concise review: quantitative detection and modeling the in vivo kinetics of therapeutic mesenchymal stem/stromal cells

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations

We thank Dr. Houng-Chi Liou of Department of Pharmacology, College of Medicine of National Taiwan University for his excellent technical support with kidney ischemia/reperfusion animal model. 

The online version contains supplementary material available at https:// doi. org/ 10. 1186/ s12929-021-00725-7.Additional file 1. Flowchart of MSC clinical study inclusion. As of October 11, 2020, 1,242 registered studies were identified on clinicaltrials.gov by searching keywords "mesenchymal stem cell" or "mesenchymal stromal cell". After excluding studies with no longer available/ suspended/ temporarily not available/ terminated/ unknown/ withdrawn status, unknown phase information, and studies that did not use MSCs in their intervention arm, 639 studies remained. Nine of these 639 studies investigated MSCs from two tissue origins, generating a total of 648 studies for analysis.

Breakdown of MSC-related clinical studies by disease indication. The included studies for analysis are as illustrated in Additional file 1.